<html>
 <head> 
 </head> 
 <body lang="EN-US" link="blue" vlink="purple"> 
  <text encoding="windows-1252" id="http://medicine.ucsf.edu/housestaff/handbook/HospH2002_C7.htm" title="HEMATOLOGY / ONCOLOGY"> 
   <meta content="Microsoft Office HTML Filter 2.0" name="Generator"> 
   <meta content="text/html; charset=utf-8" http-equiv="Content-Type"> 
   <meta content="Microsoft Word 9" name="Originator"> 
   <title>    &lt;span __num="0"&gt;     HEMATOLOGY / ONCOLOGY    &lt;/span&gt;   </title> 
   <style>    <span __num="1">     &lt;!-- p.MsoNormal, li.MsoNormal, div.MsoNormal	{	margin:0in;	margin-bottom:.0001pt;	font-size:10.0pt;	font-family:"Times New Roman";}h1	{margin:0in;	margin-bottom:.0001pt;	page-break-after:avoid;	font-size:14.0pt;	font-family:"Times New Roman";	color:blue;}h2	{margin:0in;	margin-bottom:.0001pt;	page-break-after:avoid;	font-size:10.0pt;	font-family:"Times New Roman";	color:black;	font-weight:normal;	font-style:italic;}h3	{margin-top:0in;	margin-right:0in;	margin-bottom:0in;	margin-left:.25in;	margin-bottom:.0001pt;	text-indent:-.25in;	page-break-after:avoid;	font-size:10.0pt;	font-family:"Times New Roman";	color:black;	font-weight:normal;	font-style:italic;}h4	{margin:0in;	margin-bottom:.0001pt;	page-break-after:avoid;	font-size:10.0pt;	font-family:"Times New Roman";	color:black;}h5	{margin:0in;	margin-bottom:.0001pt;	text-align:center;	page-break-after:avoid;	font-size:10.0pt;	font-family:Helvetica;	color:black;	text-decoration:underline;}h6	{margin:0in;	margin-bottom:.0001pt;	page-break-after:avoid;	font-size:10.0pt;	font-family:"Times New Roman";	color:black;	text-decoration:underline;}p.MsoHeading7, li.MsoHeading7, div.MsoHeading7	{margin-top:0in;	margin-right:0in;	margin-bottom:0in;	margin-left:13.7pt;	margin-bottom:.0001pt;	text-indent:-13.7pt;	page-break-after:avoid;	font-size:10.0pt;	font-family:"Times New Roman";	color:black;	font-weight:bold;	text-decoration:underline;}p.MsoHeading8, li.MsoHeading8, div.MsoHeading8	{margin:0in;	margin-bottom:.0001pt;	text-align:center;	page-break-after:avoid;	font-size:10.0pt;	font-family:"Times New Roman";	color:black;	font-weight:bold;}p.MsoHeading9, li.MsoHeading9, div.MsoHeading9	{margin-top:0in;	margin-right:0in;	margin-bottom:0in;	margin-left:.25in;	margin-bottom:.0001pt;	text-indent:-.25in;	page-break-after:avoid;	font-size:10.0pt;	font-family:"Times New Roman";	color:black;	font-weight:bold;}p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText	{margin:0in;	margin-bottom:.0001pt;	font-size:10.0pt;	font-family:"Times New Roman";}p.MsoHeader, li.MsoHeader, div.MsoHeader	{margin:0in;	margin-bottom:.0001pt;	font-size:10.0pt;	font-family:"Times New Roman";}p.MsoFooter, li.MsoFooter, div.MsoFooter	{margin:0in;	margin-bottom:.0001pt;	font-size:10.0pt;	font-family:"Times New Roman";}span.MsoFootnoteReference	{vertical-align:super;}p.MsoTitle, li.MsoTitle, div.MsoTitle	{margin:0in;	margin-bottom:.0001pt;	text-align:center;	font-size:11.0pt;	font-family:"Times New Roman";	color:black;	font-weight:bold;}p.MsoBodyText, li.MsoBodyText, div.MsoBodyText	{margin:0in;	margin-bottom:.0001pt;	font-size:10.0pt;	font-family:"Times New Roman";	color:black;}p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent	{margin-top:0in;	margin-right:0in;	margin-bottom:0in;	margin-left:.25in;	margin-bottom:.0001pt;	font-size:10.0pt;	font-family:"Times New Roman";	color:black;}p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle	{margin:0in;	margin-bottom:.0001pt;	font-size:12.0pt;	font-family:"Times New Roman";	font-weight:bold;}p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2	{margin:0in;	margin-bottom:.0001pt;	font-size:11.0pt;	font-family:"Times New Roman";	color:black;}a:link, span.MsoHyperlink	{color:blue;	text-decoration:underline;}a:visited, span.MsoHyperlinkFollowed	{color:purple;	text-decoration:underline;}p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap	{margin:0in;	margin-bottom:.0001pt;	background:navy;	font-size:10.0pt;	font-family:Tahoma;}span.msodel0	{	color:red;	display:none;	text-decoration:line-through;}ol	{margin-bottom:0in;}ul	{margin-bottom:0in;}--&gt;    </span>   </style> 
   <div class="Section1"> 
    <p class="MsoNormal"> <b> <i> <span style="font-size:22.0pt;font-family:&quot;Garamond Book&quot;;color:#3366FF"> <span __num="2" __label="true"> Hematology/Oncology </span> </span> </i> </b> </p> 
    <p class="MsoNormal"> <span style="font-size:9.0pt;color:#3366FF"> <span __num="3" __label="true"> Garth A.Beinart, M.D. </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:9.0pt;color:#3366FF"> <span __num="4" __label="true"> Sumitra Chari,M.D. </span> </span> </p> 
    <p align="left" class="MsoTitle" style="text-align:left"> <span style="font-size:9.0pt;color:#3366FF;font-weight:normal"> <span __num="5" __label="true"> Willis H. Navarro, M.D. </span> </span> </p> 
    <p class="MsoTitle"> <i> <span style="font-family:&quot;Garamond Book&quot;;font-weight:normal"> </span> </i> </p> 
    <p class="MsoSubtitle"> <span style="font-weight:normal"> <a href="#_ANEMIA_OVERVIEW"> <span __num="6"> Anemia overview </span> </a> </span> </p> 
    <p class="MsoSubtitle"> <span style="font-weight:normal"> <a href="#_MICROCYTIC_ANEMIA_(MCV"> <span __num="7"> Microcytic anemia </span> </a> </span> </p> 
    <p class="MsoSubtitle"> <span style="font-weight:normal"> <a href="#_NORMOCYTIC_ANEMIA_(MCV"> <span __num="8"> Normocytic anemia </span> </a> </span> </p> 
    <p class="MsoSubtitle"> <span style="font-weight:normal"> <a href="#_MACROCYTIC_ANEMIA_(MCV"> <span __num="9"> Macrocytic anemia </span> </a> </span> </p> 
    <p class="MsoSubtitle"> <span style="font-weight:normal"> <a href="#_DEEP_VEIN_THROMBOSIS"> <span __num="10"> Deep vein thrombosis </span> </a> </span> </p> 
    <p class="MsoSubtitle"> <span style="font-weight:normal"> <a href="#_HEPARIN"> <span __num="11"> Heparin </span> </a> </span> </p> 
    <p class="MsoSubtitle"> <span style="font-weight:normal"> <a href="#_WARFARIN"> <span __num="12"> Warfarin </span> </a> </span> </p> 
    <p class="MsoSubtitle"> <span style="font-weight:normal"> <a href="#_OUTPATIENT_THERAPY_FOR"> <span __num="13"> Outpatient therapy for venous thromboembolism </span> </a> </span> </p> 
    <p class="MsoSubtitle"> <span style="font-weight:normal"> <a href="#_SUPRATHERAPEUTIC_PT/PTT"> <span __num="14"> Supratherapeutic PT/PTT </span> </a> </span> </p> 
    <p class="MsoSubtitle"> <span style="font-weight:normal"> <a href="#_UREMIC_BLEEDING"> <span __num="15"> Uremic bleeding </span> </a> </span> </p> 
    <p class="MsoSubtitle"> <span style="font-weight:normal"> <a href="#_BLOOD_PRODUCTS_–"> <span __num="16"> Blood products – components </span> </a> </span> </p> 
    <p class="MsoSubtitle"> <span style="font-weight:normal"> <a href="#_BLOOD_PRODUCTS_–_1"> <span __num="17"> Blood products – complications </span> </a> </span> </p> 
    <p class="MsoSubtitle"> <span style="font-weight:normal"> <a href="#_NEUTROPENIC_FEVER:_ABSOLUTE"> <span __num="18"> Neutropenic fever </span> </a> </span> </p> 
    <p class="MsoSubtitle"> <span style="font-weight:normal"> <a href="#_SICKLE_CELL_PAIN"> <span __num="19"> Sickle cell pain crisis </span> </a> </span> </p> 
    <p class="MsoSubtitle"> <span style="font-weight:normal"> <a href="#_THROMBOCYTOPENIA"> <span __num="20"> Thrombocytopenia </span> </a> </span> </p> 
    <p class="MsoSubtitle"> <span style="font-weight:normal"> <a href="#_HEPARIN-INDUCED_THROMBOCYTOPENIA_(HIT)"> <span __num="21"> Heparin-inducedthrombocytopenia </span> </a> </span> </p> 
    <p class="MsoSubtitle"> <span style="font-weight:normal"> <a href="#_BONE_MARROW_TRANSPLANT"> <span __num="22"> Bone marrow transplant—potential complications </span> </a> </span> </p> 
    <p class="MsoSubtitle"> <span style="font-weight:normal"> <a href="#_BMT_–_ACUTE"> <span __num="23"> BMT—acutegraft vs. host disease staging and grading </span> </a> </span> </p> 
    <p class="MsoSubtitle"> <span style="font-weight:normal"> <a href="#_ONCOLOGIC_EMERGENCIES"> <span __num="24"> Oncologic emergencies </span> </a> </span> </p> 
    <p class="MsoSubtitle"> <span style="font-weight:normal"> <a href="#_PAIN_MANAGEMENT"> <span __num="25"> Pain management </span> </a> </span> </p> 
    <p class="MsoSubtitle"> <span style="font-weight:normal"> <a href="#_COMMON_CHEMOTHERAPY_SIDE"> <span __num="26"> Common chemotherapy side effects </span> </a> </span> </p> 
    <p class="MsoSubtitle"> </p> 
    <p class="MsoSubtitle"> </p> 
    <h1> <a name="_ANEMIA_OVERVIEW"> </a> <span __num="27" __label="true"> ANEMIA OVERVIEW </span> </h1> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="28"> 1. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="29" __label="true"> Symptoms </span> </span> </b> <span style="font-size:11.0pt;color:black"> <span __num="30" __label="true"> ofanemia include fatigue, dyspnea on exertion, and even angina. </span> <b> <span __num="31" __label="true"> Physicalexam </span> </b> <span __num="32" __label="true"> findings include pallor, tachycardia, and jaundice. </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoBodyText" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt"> <span __num="33"> 2. </span> </span> <span style="font-size:7.0pt"> </span> <span style="font-size:11.0pt"> <span __num="34" __label="true"> To generate a </span> <b> <span __num="35" __label="true"> differential diagnosis </span> </b> <span __num="36" __label="true"> anemia, first categorize the type of anemia (microcytic, normocytic,macrocytic) by MCV and furthermore with the ferritin and reticulocytecount.&nbsp; Then, exam the peripheral smear: findings on the smear will narrowyour differential, suggest additional medical problems the patient may have ( </span> <i> <span __num="37" __label="true"> i.e. </span> </i> <span __num="38" __label="true"> target cells and liver disease, spur cells and uremia with uremic plateletdysfunction), and may reveal diagnoses such as microangiopathic hemolyticanemia (MAHA) in a timely fashion.&nbsp; Finally, order additional tests toconfirm your diagnosis and remember to get your tests before transfusing thepatient. </span> </span> </p> 
    <p class="MsoBodyText"> <span style="font-size:11.0pt"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="39"> 3. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="40" __label="true"> Factoids: </span> </span> </b> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.25in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="41"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="42" __label="true"> Hospitalized patients will drop theirhematocrit 1% per day from blood draws. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="43"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="44" __label="true"> Epogen® causes hypertension if thehematocrit is raised &gt; 35% in ESRD and does not work in the setting of irondeficiency. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="45"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="46" __label="true"> Follow the hemoglobin and not thehematocrit. The hematocrit is calculated from two measured values and has a </span> </span> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="47" __label="true"> ± </span> </span> <span style="font-size:11.0pt;color:black"> <span __num="48" __label="true"> 3 point range for error. </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal"> <b> <span style="font-size:12.0pt;font-family:Arial;color:black"> </span> </b> </p> 
    <h1> <a name="_MICROCYTIC_ANEMIA_(MCV"> </a> <span __num="49" __label="true"> MICROCYTIC ANEMIA (MCV &lt; 80) </span> </h1> 
    <p class="MsoNormal"> <b> <span style="font-size:12.0pt;font-family:Arial;color:black"> </span> </b> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="50"> 1. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="51" __label="true"> Work-up: </span> </span> </b> <span style="font-size:11.0pt;color:black"> <span __num="52" __label="true"> orderiron, ferritin, transferrin, and if possible a red cell distribution width(RDW). </span> </span> </p> 
    <p class="MsoNormal"> <b> <span style="font-size:11.0pt;color:black"> </span> </b> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="53"> 2. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="54" __label="true"> Iron deficiency: </span> </span> </b> <span style="font-size:11.0pt;color:black"> <span __num="55" __label="true"> On physical exam, look for koilonychia, atrophic tongue.&nbsp;Iron deficiency usually does not cause a microcytic anemia until the hematocritdrops below 30%.&nbsp; Ferritin is useful for diagnosing iron deficiency. Thelikelihood ratios are as follows: for a ferritin &lt;15 the LR=50 in favor ofiron deficiency anemia; for a ferritin &lt;25 the LR=10, specificity of 98%;for a ferritin &gt;100 the LR=0.1. Since ferritin is an acute phase reactant,some say it should not be used in the setting of inflammation; others say thatin chronic inflammation a ferritin &lt; 50 is highly suggestive of irondeficiency.&nbsp; Iron is low and transferrin or TIBC (total iron bindingcapacity) is high, which makes the transferrin saturation (iron divided bytransferrin) low: a saturation &lt;10% has a specificity of 88%. The RDW(reflecting anisocytosis) is high. Once you’ve made the diagnosis, rule out GIbleeding: around 60% of patients will have GI lesions. Order stool guiaics, acolonoscopy, and possibly an EGD.&nbsp; With treatment, the hematocrit shouldbe normal in 2 months; continue iron treatment 4-6 months to replete stores.Common side effect of oral iron is constipation.&nbsp; IV iron available ifpatient refractory to PO, but has increased risk of anaphylaxis. Each PRBCtransfused contains 200 mg elemental iron. </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="56"> 3. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="57" __label="true"> Sideroblastic anemia: </span> </span> </b> <span style="font-size:11.0pt;color:black"> <span __num="58" __label="true"> hereditary cases are usually microcytic while acquiredsideroblastic anemia may be normocytic. Acquired causes include lead, INH,EtOH, B </span> <sub> <span __num="59" __label="true"> 6 </span> </sub> <span __num="60" __label="true"> deficiency. Basophilic stippling and dimorphic RBCmorphology is seen on peripheral blood smear. </span> </span> </p> 
    <p class="MsoNormal"> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="61"> 4. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="62" __label="true"> Thalassemia: </span> </span> </b> <span style="font-size:11.0pt;color:black"> <span __num="63" __label="true"> The Mentzer index may be helpful: (MCV/RBC count) &lt; 13 favors thalassemiaover iron deficiency.&nbsp; This test has a high sensitivity but lowspecificity.&nbsp; Basically in iron deficiency, the marrow can’t produce RBCsand they’re small so the RBC count will be low along with the MCV.&nbsp; Inthalassemia, RBC production is preserved, though the cells are small andfragile.&nbsp; So the RBC count is normal with a low MCV.&nbsp; This conceptmay be more helpful than remembering the Mentzer index.&nbsp; The RDW inthalassemia, unlike iron deficiency, is normal and may be a more accuratediscriminant function in differentiating between the two.&nbsp; Make thediagnosis of beta-thalassemia with hemoglobin electrophoresis.Alpha-thalassemia will not show up on electrophoresis: it is diagnosed bymolecular diagnostic techniques. Order an “A-thal” on the lab slip. Think of </span> <b> <span __num="64" __label="true"> A </span> </b> <span __num="65" __label="true"> lphathalassemia in </span> <b> <span __num="66" __label="true"> A </span> </b> <span __num="67" __label="true"> sians.&nbsp; Beta thal in Meditteraneans.&nbsp;&nbsp;Differential diagnosis for target cells on smear: beta thalassemia, hemoglobinC disease, liver disease, beta-lipoproteinemia.&nbsp; In general you should notsee targets in sickle cell unless they are sickle-thalassemia or sickle-C. </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="68"> 5. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="69" __label="true"> Anemia of chronic disease: </span> </span> </b> <span style="font-size:11.0pt;color:black"> <span __num="70" __label="true"> Chronic inflammatory diseases, that is, such as cancer andcollagen-vascular diseases. Transferrin is decreased, saturation increased,iron low, ferritin normally increased (non specific for chronic disease). TheMCV rarely falls below 78, though the patient can become microcytic becausethey are functionally deficient of iron. </span> </span> </p> 
    <h1> <span style="font-weight:normal"> </span> </h1> 
    <p class="MsoNormal"> <i> <span style="font-size:9.0pt;font-family:Arial"> <span __num="71" __label="true"> GuyattGH, Oxman AD, Ali M, Willan A, McIlroy W, Patterson C. Laboratory diagnosis ofiron-deficiency anemia: an overview.&nbsp; J Gen Intern Med. 1992Mar-Apr;7(2):145-53. </span> </span> </i> </p> 
    <p class="MsoNormal"> </p> 
    <p class="MsoNormal"> </p> 
    <h1> <a name="_NORMOCYTIC_ANEMIA_(MCV"> </a> <span __num="72" __label="true"> NORMOCYTIC ANEMIA (MCV 80-100) </span> </h1> 
    <h1> </h1> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="73"> 1. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="74" __label="true"> Reticulocytes: </span> </span> </b> </p> 
    <ul style="margin-top:0in" type="disc"> 
     <li class="MsoNormal" style="color:black;"> <span style="font-size:11.0pt"> <span __num="75" __label="true"> First check a reticulocyte count.&nbsp; Your goal is to come up with a </span> <i> <span __num="76" __label="true"> reticulocyte index </span> </i> <span __num="77" __label="true"> (RI). </span> </span> </li> 
     <li class="MsoNormal" style="color:black;"> <span style="font-size:11.0pt"> <span __num="78" __label="true"> If your lab gives you an </span> <i> <span __num="79" __label="true"> absolute </span> </i> <span __num="80" __label="true"> reticulocyte count, make into a </span> <i> <span __num="81" __label="true"> percent </span> </i> <span __num="82" __label="true"> reticulocyte count by dividing by the RBC count. </span> <i> <span __num="83" __label="true"> Make sure to convert your units! </span> </i> </span> </li> 
     <li class="MsoNormal" style="color:black;"> <span style="font-size:11.0pt"> <span __num="84" __label="true"> Now correct the reticulocyte count for the patient’s hematocrit (HCT).&nbsp; Corrected reticulocyte count = % reticulocytes x (actual hematocrit </span> </span> <span style="font-size:11.0pt;     font-family:Symbol"> <span __num="85" __label="true"> ¸ </span> </span> <span style="font-size:11.0pt"> <span __num="86" __label="true"> ideal hematocrit). </span> </span> </li> 
     <li class="MsoNormal" style="color:black;"> <span style="font-size:11.0pt"> <span __num="87" __label="true"> Now correct for early release of reticulocytes by dividing by (1 + 0.5 </span> <i> <span __num="88" __label="true"> x </span> </i> <span __num="89" __label="true"> ) where </span> <i> <span __num="90" __label="true"> x </span> </i> <span __num="91" __label="true"> is 1 for every drop of 10% in the hematocrit.&nbsp; For example, divide by 1.5 for HCT=35% and divide by 2 for HCT=25%. </span> </span> </li> 
     <li class="MsoNormal" style="color:black;"> <span style="font-size:11.0pt"> <span __num="92" __label="true"> You now have the reticulocyte index (RI).&nbsp; If the RI &lt; 2 for HCT 10-35%, or &lt; 3 for HCT &lt; 10%, your patient has a hypoproliferative anemia. </span> </span> </li> 
    </ul> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="93"> 2. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="94" __label="true"> Decreased reticulocyte count: </span> </span> </b> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="95"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="96" __label="true"> Primary bone marrow failure: </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="97"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="98" __label="true"> Aplastic anemia/red cell aplasia </span> </span> </i> <span style="font-size:11.0pt;color:black"> <span __num="99" __label="true"> : diagnosed by bone marrow biopsy. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="100"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="101" __label="true"> Myelophthisis </span> </span> </i> <span style="font-size:11.0pt;color:black"> <span __num="102" __label="true"> : (replacement of the bone marrow) teardrops on smear </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="103"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="104" __label="true"> Myelodysplastic syndrome </span> </span> </i> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.25in"> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="105"> · </span> </span> <span style="font-size:7.0pt"> </span> <span style="font-size:11.0pt;color:black"> <span __num="106" __label="true"> Secondary bone marrow failure: </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="107"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="108" __label="true"> Anemia of chronic disease </span> </span> </i> <span style="font-size:11.0pt;color:black"> <span __num="109" __label="true"> : Normal or increased platelets and WBCssupport this is the diagnosis. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="110"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="111" __label="true"> Iron, B12, folate deficiency (nutritionaldeficiency) </span> </span> </i> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="112"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="113" __label="true"> Chronic kidney disease </span> </span> </i> <span style="font-size:11.0pt;color:black"> <span __num="114" __label="true"> : use erythropoeitin when the creatinineclearance drops below 30 ml/min. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="115"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="116" __label="true"> Hypersplenism </span> </span> </i> <span style="font-size:11.0pt;color:black"> <span __num="117" __label="true"> : usually anemia is concomitant with mildpancytopenia. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="118"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="119" __label="true"> Hypothyroidism </span> </span> </i> <span style="font-size:11.0pt;color:black"> <span __num="120" __label="true"> : especially in the elderly </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="121"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="122" __label="true"> Multiple myeloma </span> </span> </i> <span style="font-size:11.0pt;color:black"> <span __num="123" __label="true"> : check SPEP, UPEP </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="124"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="125" __label="true"> HIV/AIDS </span> </span> </i> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="126"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="127" __label="true"> Mixed: e.g. </span> </span> </i> <span style="font-size:11.0pt;color:black"> <span __num="128" __label="true"> an alcoholic with megaloblastic anemiafrom folate deficiency, and iron deficiency from GI bleeding. The MCV isnormal, but the RDW is increased reflecting anisocytosis (cells of varyingsizes). </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="129"> 4. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="130" __label="true"> Increased reticulocyte count </span> </span> </b> <span style="font-size:11.0pt;color:black"> <span __num="131" __label="true"> : check smear for schistocytes (intravascular hemolysis)and/or spherocytes (extravascular hemolysis). </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="132"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="133" __label="true"> Acute blood loss </span> </span> </i> <span style="font-size:11.0pt;color:black"> <span __num="134" __label="true"> : If you can’t find a source, don’t forgetto rule out occult retroperitoneal bleed. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="135"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="136" __label="true"> Correction </span> </span> </i> <span style="font-size:11.0pt;color:black"> <span __num="137" __label="true"> : of a production deficit. Peak MCV at7-10 days. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="138"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="139" __label="true"> Hemolysis </span> </span> </i> <span style="font-size:11.0pt;color:black"> <span __num="140" __label="true"> : see below. </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="141"> 5. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="142" __label="true"> Hemolysis: </span> </span> </b> </p> 
    <ul style="margin-top:0in" type="disc"> 
     <li class="MsoNormal" style="color:black;"> <span style="font-size:11.0pt"> <span __num="143" __label="true"> Classification is based on: </span> </span> </li> 
    </ul> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.25in"> <span style="font-size:11.0pt"> <span __num="144"> - </span> </span> <span style="font-size:7.0pt"> </span> <span style="font-size:11.0pt;color:black"> <span __num="145" __label="true"> Site of hemolysis(intravascular vs. extravascular) </span> <i> <span __num="146" __label="true"> or </span> </i> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.25in"> <span style="font-size:11.0pt"> <span __num="147"> - </span> </span> <span style="font-size:7.0pt"> </span> <span style="font-size:11.0pt;color:black"> <span __num="148" __label="true"> Intrinsic (RBC defect) vs. anacquired extrinsic mechanism (where transfused cells will have a shortened lifespan). </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.25in"> <span style="font-size:11.0pt"> <span __num="149"> - </span> </span> <span style="font-size:7.0pt"> </span> <span style="font-size:11.0pt;color:black"> <span __num="150" __label="true"> Send LDH, total and direct bilirubin,and possibly haptoglobin (level &lt; 25 is 96% specific for hemolysis).&nbsp; Anormal LDH and haptoglobin &gt; 25 helped rule out hemolysis in one smallstudy.&nbsp; Haptoglobin overall is not very useful as it takes one week toreturn, is an acute phase reactant, and is </span> <i> <span __num="151" __label="true"> very </span> </i> <span __num="152" __label="true"> sensitive (leading todecreased specificity). </span> </span> </p> 
    <ul style="margin-top:0in" type="disc"> 
     <li class="MsoNormal" style="color:black;"> <span style="font-size:11.0pt"> <span __num="153" __label="true"> Intravascular causes:&nbsp; red cell fragmentation syndromes, PNH, immediate transfusion reactions. Look for schistocytes and urine hemoglobin/hemosiderin/heme+ (sensitive). </span> </span> </li> 
     <li class="MsoNormal" style="color:black;"> <span style="font-size:11.0pt"> <span __num="154" __label="true"> Extravascular causes: RBCs destroyed by the reticuloendothelial system. </span> </span> </li> 
     <li class="MsoNormal" style="color:black;"> <span style="font-size:11.0pt"> <span __num="155" __label="true"> Extrinsic causes: </span> </span> </li> 
    </ul> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.25in"> <span style="font-size:11.0pt"> <span __num="156"> - </span> </span> <span style="font-size:7.0pt"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="157" __label="true"> Hypersplenism </span> </span> </i> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="158"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="159" __label="true"> Antibody-mediated </span> </span> </i> <span style="font-size:11.0pt;color:black"> <span __num="160" __label="true"> : warm (IgG) vs. cold (Ig </span> <b> <span __num="161" __label="true"> M </span> </b> <span __num="162" __label="true"> ) think </span> <b> <span __num="163" __label="true"> M </span> </b> <span __num="164" __label="true"> ono, </span> <b> <span __num="165" __label="true"> M </span> </b> <span __num="166" __label="true"> ycoplasma;check Coomb’s. Spherocytes are on the smear. Drugs are a bigoffender as well. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="167"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="168" __label="true"> Trauma/ Red Cell fragmentation </span> </span> </i> <span style="font-size:11.0pt;color:black"> <span __num="169" __label="true"> : heart valve, hemodialysis, malignantHTN, vasculitis, HELLP, cardiopulmonary bypass, TTP/HUS, DIC.&nbsp; Look forschistocytes and helmet cells (even 1-2 per HPF), and spherocytes. Remember:DIC increases INR and PTT, HUS and TTP do not. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="170"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="171" __label="true"> Infection/toxin: </span> </span> </i> <span style="font-size:11.0pt;color:black"> <span __num="172" __label="true"> malaria, babesiosis, clostridia,brown-recluse, copper (Wilson’s disease). </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.25in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="173"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="174" __label="true"> Intrinsic defects: </span> <i> <span __num="175" __label="true"> all are hereditaryexcept PNH. </span> </i> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="176"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="177" __label="true"> Membrane: </span> </span> </i> <span style="font-size:11.0pt;color:black"> <span __num="178" __label="true"> Hereditary spherocytosis, hereditaryelliptocytosis. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="179"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="180" __label="true"> Enzyme:&nbsp; e.g. </span> </span> </i> <span style="font-size:11.0pt;color:black"> <span __num="181" __label="true"> G6PD deficiency: normal smear andCoomb’s. Check G6PD levels, which may be normal after an acute hemolyticepisode or post transfusion. Consider this in HIV patients, particularlyAfrican Americans, taking PCP prophylaxis. Although this is X-linked recessive,it may still occur in females due to lyonization. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="182"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="183" __label="true"> Hemoglobinopathy: </span> </span> </i> <span style="font-size:11.0pt;color:black"> <span __num="184" __label="true"> sickle cell, thalassemias, Hgb C, Hgb E. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="185"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="186" __label="true"> PNH </span> </span> </i> <span style="font-size:11.0pt;color:black"> <span __num="187" __label="true"> : complement-mediated lysis. Consider with pancytopenia, unexplainedthrombosis (especially intra-abdominal) and an elevated reticulocyte count andLDH. A rare diagnosis. </span> </span> </p> 
    <p class="MsoNormal"> <b> <span style="font-size:12.0pt;font-family:Arial;color:black"> </span> </b> </p> 
    <p class="MsoNormal"> <i> <span style="font-size:9.0pt;font-family:Arial;color:black"> <span __num="188" __label="true"> Marchand A, Galen RS, Van Lente F.&nbsp;&nbsp; The predictivevalue of serum haptoglobin in hemolytic disease. </span> </span> </i> </p> 
    <p class="MsoNormal"> <i> <span style="font-size:9.0pt;font-family:Arial;color:black"> <span __num="189" __label="true"> JAMA. 1980 May 16;243(19):1909-11. </span> </span> </i> <b> <span style="font-size:12.0pt;font-family:Arial;color:black"> <br clear="all" style="page-break-before:always"> </span> </b> </p> 
    <p class="MsoNormal"> <b> <span style="font-size:12.0pt;font-family:Arial;color:black"> </span> </b> </p> 
    <h1> <a name="_MACROCYTIC_ANEMIA_(MCV"> </a> <span __num="190" __label="true"> MACROCYTIC ANEMIA (MCV &gt; 100) </span> </h1> 
    <h1> </h1> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="191"> 1. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="192" __label="true"> Megaloblastic </span> </span> </b> <span style="font-size:11.0pt;color:black"> <span __num="193" __label="true"> :hypersegmented neutrophils (&gt; 5% of neutrophils with 5 lobes or &gt; 1% with6 lobes) are seen on the smear. An MCV &gt; 120 is almost pathognomonic formegaloblastic anemia. Ovalocytes may be seen, but are nonspecific. On physicalexam, look for atrophic tongue. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="194"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="195" __label="true"> B12 deficiency </span> </span> </i> <span style="font-size:11.0pt;color:black"> <span __num="196" __label="true"> : diagnose with serum B12. This value maybe falsely decreased secondary to folate deficiency or type 1 cryoglobulinemia( </span> <i> <span __num="197" __label="true"> e.g. </span> </i> <span __num="198" __label="true"> multiple myeloma, Waldenstrom’s macroglobulinemia). Look forsubacute combined degeneration.&nbsp; Can send homocysteine and methylmalonicacid.&nbsp; Schilling test to look at source of deficiency. May havepancytopenia. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="199"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="200" __label="true"> Folate deficiency </span> </span> </i> <span style="font-size:11.0pt;color:black"> <span __num="201" __label="true"> : diagnose with RBC-Folate level.&nbsp;(Serum folate fluctuates and is a poor proxy for folate stores).&nbsp; May befalsely low secondary to B12 deficiency. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="202"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="203" __label="true"> Drug-induced </span> </span> </i> <span style="font-size:11.0pt;color:black"> <span __num="204" __label="true"> : chemo, methotrexate (MTX), hydroxyurea,azathioprine, etc. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="205"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="206" __label="true"> Note: repletion of vitamin B12 shouldalways accompany folate and iron therapy until you are sure the patient doesnot have multiple deficiencies, in order to avoid aplastic-type crisis and/orhigh output CHF.&nbsp; In addition, folate may partially correct themegaloblastic anemia of B12 deficiency while the neurologic symptoms progress. </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="207"> 2. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="208" __label="true"> Non-megaloblastic </span> </span> </b> <span style="font-size:11.0pt;color:black"> <span __num="209" __label="true"> : MCV &lt; 110 in most cases. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="210"> · </span> </span> <span style="font-size:7.0pt"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="211" __label="true"> Alcoholism </span> </span> </i> <span style="font-size:11.0pt;color:black"> <span __num="212" __label="true"> : most common cause of macrocytic anemia. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="213"> · </span> </span> <span style="font-size:7.0pt"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="214" __label="true"> Liver disease </span> </span> </i> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.25in"> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="215"> · </span> </span> <span style="font-size:7.0pt"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="216" __label="true"> Hypothyroidism </span> </span> </i> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="217"> · </span> </span> <span style="font-size:7.0pt"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="218" __label="true"> Reticulocytosis </span> </span> </i> <span style="font-size:11.0pt;color:black"> <span __num="219" __label="true"> : although the reticulocyte MCV is 160 microns, reticulocytosis rarelycauses an MCV above 110.&nbsp; Polychromasia is seen on smear. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="220"> · </span> </span> <span style="font-size:7.0pt"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="221" __label="true"> Spurious </span> </span> </i> <span style="font-size:11.0pt;color:black"> <span __num="222" __label="true"> : hyperglycemia and hypernatremia, secondary to osmotic swelling. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="223"> · </span> </span> <span style="font-size:7.0pt"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="224" __label="true"> Aplastic </span> </span> </i> <span style="font-size:11.0pt;color:black"> <i> <span __num="225" __label="true"> anemia </span> </i> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="226"> · </span> </span> <span style="font-size:7.0pt"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="227" __label="true"> Myelodysplastic syndromes </span> </span> </i> <span style="font-size:11.0pt;color:black"> <span __num="228" __label="true"> : giant platelets, hypogranulated neutrophils, bi-lobedneutrophils. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="229"> · </span> </span> <span style="font-size:7.0pt"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="230" __label="true"> Drugs: </span> </span> </i> <span style="font-size:11.0pt;color:black"> <span __num="231" __label="true"> anticonvulsants, AZT. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in"> <b> <span style="font-size:11.0pt;color:black"> </span> </b> </p> 
    <p class="MsoNormal"> <i> <span style="font-size:9.0pt;font-family:Arial;color:black"> <span __num="232" __label="true"> Hoffbrand V, Provan D.&nbsp;&nbsp; ABC of clinical haematology.Macrocytic anaemias.&nbsp; BMJ. 1997 Feb 8;314(7078):430-3. </span> </span> </i> </p> 
    <h6> <span style="font-weight:normal"> </span> </h6> 
    <span style="font-size:14.0pt;font-family:&quot;Times New Roman&quot;;color:blue;"> <br clear="all" style="page-break-before:always"> </span> 
    <h1> <a name="_DEEP_VEIN_THROMBOSIS"> </a> <span __num="233" __label="true"> DEEP VEIN THROMBOSIS </span> </h1> 
    <p class="MsoBodyText"> <span style="color:windowtext"> </span> </p> 
    <p class="MsoBodyText" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt"> <span __num="234"> 1. </span> </span> <span style="font-size:7.0pt"> </span> <span style="font-size:11.0pt"> <span __num="235" __label="true"> See also </span> <i> <a href="HospH2002_C4.htm#PE"> <span __num="236" __label="true"> Pulmonary:Pulmonary embolism </span> </a> <span __num="237"> . </span> </i> </span> </p> 
    <p class="MsoBodyText"> <span style="font-size:11.0pt"> </span> </p> 
    <p class="MsoBodyText" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt"> <span __num="238"> 2. </span> </span> <span style="font-size:7.0pt"> </span> <span style="font-size:11.0pt"> <span __num="239" __label="true"> Over 9 in 10 pulmonary emboli originatefrom DVTs, and the treatment of PE and DVT are usually identical. </span> </span> </p> 
    <p class="MsoBodyText"> <span style="font-size:11.0pt"> </span> </p> 
    <p class="MsoBodyText" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt"> <span __num="240"> 3. </span> </span> <span style="font-size:7.0pt"> </span> <span style="font-size:11.0pt"> <span __num="241" __label="true"> DVTs are associated with calf pain andtenderness. Homan’s sign—pain when dorsiflexing the foot with the kneeextended—is neither sensitive nor specific and should be abandoned. </span> </span> </p> 
    <p class="MsoBodyText"> <span style="font-size:11.0pt"> </span> </p> 
    <p class="MsoBodyText" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt"> <span __num="242"> 4. </span> </span> <span style="font-size:7.0pt"> </span> <span style="font-size:11.0pt"> <span __num="243" __label="true"> DVT prophylaxis should be addressed inall inpatients. Encourage early ambulation and order physical therapy whenindicated. Obtain prophylaxis with sequential compression devices, low dose ultrafractionatedheparin, or low molecular weight heparin ( </span> <i> <span __num="244" __label="true"> e.g. </span> </i> <span __num="245" __label="true"> enoxaparin).&nbsp; Seealso </span> <i> <a href="HospH2002_C14.htm#_DVT/PE_PROPHYLAXIS"> <span __num="246" __label="true"> Medical Consultation:DVT/PE prophylaxis </span> </a> <span __num="247"> . </span> </i> </span> </p> 
    <p class="MsoBodyText"> <span style="font-size:11.0pt"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="248"> 5. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="249" __label="true"> Simple clinical model to diagnose DVT: </span> </span> </b> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="250"> · </span> </span> <span style="font-size:7.0pt"> </span> <span style="font-size:11.0pt;color:black"> <span __num="251" __label="true"> Give the patient one (1) point for each of the following (if theyare present): active cancer, immobilization, bedridden &gt; than 3 days due tosurgery, localized tenderness, entire leg swelling, asymmetric &gt; 3 cm calfswelling,&nbsp; pitting edema, or collateral superficial veins (nonvaricose). </span> </span> </p> 
    <ul style="margin-top:0in" type="disc"> 
     <li class="MsoNormal" style="color:black;"> <span style="font-size:11.0pt"> <span __num="252" __label="true"> Is there an alternative diagnosis that is as likely or more likely than DVT?&nbsp; If yes, subtract 2 points. </span> </span> </li> 
     <li class="MsoNormal" style="color:black;"> <span style="font-size:11.0pt"> <span __num="253" __label="true"> Score &gt; 3: </span> <i> <span __num="254" __label="true"> high probability of DVT, prevalence of DVT 75% </span> </i> <span __num="255" __label="true"> . </span> </span> </li> 
     <li class="MsoNormal" style="color:black;"> <span style="font-size:11.0pt"> <span __num="256" __label="true"> Score 1-2: </span> <i> <span __num="257" __label="true"> moderate probability of DVT, prevalence of DVT 17% </span> </i> <span __num="258" __label="true"> . </span> </span> </li> 
     <li class="MsoNormal" style="color:black;"> <span style="font-size:11.0pt"> <span __num="259" __label="true"> Score 0: </span> <i> <span __num="260" __label="true"> low probability of DVT, prevalence of 3% </span> </i> <span __num="261"> . </span> </span> </li> 
    </ul> 
    <p class="MsoNormal" style="margin-left:.25in"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="262"> 6. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="263" __label="true"> Work-up of suspected DVT: </span> </span> </b> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="264"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="265" __label="true"> D-dimers </span> </span> </i> <span style="font-size:11.0pt;color:black"> <span __num="266" __label="true"> : very useful if your local hospital has the ELISA testwhich is very sensitive (good for ruling out DVT).&nbsp; Some labs use thelatex agglutination test, which is only 85-90% sensitive. Thus, in a patientwith a non-diagnostic V/Q scan (for PE) or Doppler ultrasound (for DVT), anegative D-dimer (ELISA method) means it is probably safe not to anticoagulateif your clinical suspicion is low or moderate. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="267"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="268" __label="true"> Doppler ultrasound </span> </span> </i> <span style="font-size:11.0pt;color:black"> <span __num="269" __label="true"> : This test is better at detecting DVTs abovethe knee (which, in fact, are the clinically significant ones as clots belowthe knee rarely cause pulmonary embolism).&nbsp; Ultrasound is 50% sensitive inan asymptomatic individual, and therefore cannot be used to rule out PE.Ultrasound is also less sensitive than venogram for calf DVT. </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="270"> 7. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="271" __label="true"> Hypercoagulability work-up: </span> </span> </b> </p> 
    <ol start="1" style="margin-top:0in" type="1"> 
     <li class="MsoNormal" style="color:black;"> <span style="font-size:11.0pt"> <span __num="272" __label="true"> After the first event, the hypercoaguable work-up will lead to an etiology in only 30% of patients; after the second DVT only 50% will eventually have an etiology determined.&nbsp; Moreover, only 10-20% of people with an idiopathic DVT will ever have another event. </span> </span> </li> 
    </ol> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="273"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="274" __label="true"> It is not necessary to begin the work upof anticoagulation at the time of the clot: the results won’t change yourmanagement and will take a while to come back anyway; therefore, consider anoutpatient work-up. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.25in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="275"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="276" __label="true"> Guidelines for hypercoagulability work-up: </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="277"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="278" __label="true"> Draw an extra blue top tube beforestarting heparin or warfarin if you suspect a hypercoaguable state: heparinwill interfere with assays for antithrombin III and the lupus anticoagulant. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="279"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="280" __label="true"> Protein C, S, anticardiolipin antibodies,homocysteine, prothrombin 20210A, Factor V Leiden, and MTHFR mutations (leadingto hyperhomocysteinemia) can be sent when patients are taking heparin.&nbsp; Notethat Proteins C and S are vitamin K dependent factors and will be lowered bywarfarin therapy. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="281"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="282" __label="true"> AT III, Protein C, and Protein S may betransiently depressed during the acute event, and only persistent lupusanticoagulants are associated with hypercoagulability. Therefore, repeatabnormal tests later to make an accurate diagnosis. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="283"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="284" __label="true"> Note that there is not a consensus thatall patients with unprovoked DVT/PE should have a hypercoagulabilitywork-up.&nbsp; The most common defects are not associated with recurrentdisease, and the ones that are, are uncommon.&nbsp; A targeted work-up islikely a more reasonable approach ( </span> <i> <span __num="285" __label="true"> e.g. </span> </i> <span __num="286" __label="true"> send antiphospholipid antibodyas persistent lupus anticoagulant is associated with venous/arterial recurrenceand may require a higher INR goal for warfarin therapy). </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoBodyText" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt"> <span __num="287"> 8. </span> </span> <span style="font-size:7.0pt"> </span> <b> <span style="font-size:11.0pt"> <span __num="288" __label="true"> Treatment </span> </span> </b> <span style="font-size:11.0pt"> <span __num="289" __label="true"> : typically involves heparin (or enoxaparin) andwarfarin.&nbsp; Some advocate giving patients heparin for 5 days, even if theirINR becomes therapeutic in less than 5 days. Patients should be therapeuticallyanticoagulated as soon as possible (within 24 hours). Thus, it is better toovershoot and risk bleeding than to undershoot and risk furtherembolic/thrombotic events.&nbsp; See </span> <i> <a href="#_HEPARIN"> <span __num="290" __label="true"> Hematology/Oncology:Heparin </span> </a> </i> <span __num="291" __label="true"> and </span> <i> <a href="#_WARFARIN"> <span __num="292" __label="true"> Hematology/Oncology: Warfarin </span> </a> </i> <span __num="293" __label="true"> (below). </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <i> <span style="font-size:9.0pt;font-family:Arial;color:black"> <span __num="294" __label="true"> Anand SS, Wells PS, etal.&nbsp; Does this patient have deep vein thrombosis? JAMA. 1998 Apr8;279(14):1094-9. </span> </span> </i> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <i> <span style="font-size:9.0pt;font-family:Arial;color:black"> <span __num="295" __label="true"> Seligsohn U, Lubetsky A.Genetic susceptibility to venous thrombosis. N Engl J Med. 2001 Apr19;344(16):1222-31 </span> </span> </i> </p> 
    <p class="MsoNormal"> <i> <span style="font-size:9.0pt;font-family:Arial;color:black"> <span __num="296" __label="true"> Hyers TM, Agnelli G, et al.&nbsp; Antithrombotic therapy forvenous thromboembolic disease.&nbsp; Chest. 2001 Jan;119(1 Suppl):176S-193S.. </span> </span> </i> </p> 
    <p class="MsoHeading9"> <span style="font-weight:normal"> </span> </p> 
    <p class="MsoHeading9"> <span style="font-weight:normal"> </span> </p> 
    <h1> <a name="_HEPARIN"> </a> <span __num="297" __label="true"> HEPARIN </span> </h1> 
    <p class="MsoNormal"> </p> 
    <h3> <span style="font-size:11.0pt;font-style:normal"> <span __num="298"> 1. </span> </span> <span style="font-size:7.0pt;font-style:normal"> </span> <b> <span style="font-size:11.0pt;font-style:normal"> <span __num="299" __label="true"> Risk factors for bleeding while onheparin: </span> </span> </b> </h3> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="300"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="301" __label="true"> Surgery, trauma, or stroke within theprevious 14 days. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="302"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="303" __label="true"> History of peptic ulcer disease, GIbleeding or GU bleeding. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="304"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="305" __label="true"> Platelets &lt; 150K. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="306"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="307" __label="true"> Age &gt; 70 years. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="308"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="309" __label="true"> Hepatic failure, uremia, bleedingdiathesis, brain metastases. </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="310"> 2. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="311" __label="true"> When to use low molecular weight heparin </span> </span> </b> <span style="font-size:11.0pt;color:black"> <span __num="312" __label="true"> (enoxaparin): LMWH eliminates the need tomonitor PTT and adjust dosages. You may send selected patients home withenoxaparin and warfarin, rather than keeping them in-house on heparin for 5days or until they are therapeutic on warfarin (see </span> <i> <a href="#_OUTPATIENT_THERAPY_FOR_1"> <span __num="313" __label="true"> Hematology/Oncology: Outpatient therapy forvenous thromboembolism </span> </a> </i> <span __num="314" __label="true"> ).&nbsp; Moreover, LMWH is associated with alower incidence of heparin-associated thrombocytopenia.&nbsp; Regular,ultrafractionated heparin is preferable when: </span> </span> </p> 
    <ul style="margin-top:0in" type="disc"> 
     <li class="MsoNormal"> <span style="font-size:11.0pt"> <span __num="315" __label="true"> Patients require prolonged hospitalization anyway (cost savings over enoxaparin) </span> <i> <span __num="316" __label="true"> or </span> </i> </span> </li> 
     <li class="MsoNormal"> <span style="font-size:11.0pt"> <span __num="317" __label="true"> Rapid reversal of anticoagulation might be necessary ( </span> <i> <span __num="318" __label="true"> e.g. </span> </i> <span __num="319" __label="true"> possible surgery). </span> </span> </li> 
    </ul> 
    <p class="MsoNormal" style="margin-left:.5in"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="320"> 3. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="321" __label="true"> Consider a hematology consult before using LMWH in the followingsituations: </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="322" __label="true"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="323" __label="true"> Weight &gt; 150 kg. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="324"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="325" __label="true"> Creatinine &gt; 2, or creatinine clearance&lt; 30 ml/min. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="326"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="327" __label="true"> Pregnancy. </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="328"> 4. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="329" __label="true"> For heparin sliding scale, see </span> <i> <a href="HospH2002_AppD.htm#_HEPARIN"> <span __num="330" __label="true"> Sliding Scales: Heparin </span> </a> </i> <span __num="331" __label="true"> . </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal"> <i> <span style="font-size:9.0pt;font-family:Arial;color:black"> <span __num="332" __label="true"> Hirsh J, Warkentin TE, et al.&nbsp; Heparin andlow-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing,monitoring, efficacy, and safety.&nbsp; Chest. 2001 Jan;119(1 Suppl):64S-94S. </span> </span> </i> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <b> <span style="font-size:12.0pt;font-family:Arial;color:black"> </span> </b> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <b> <span style="font-size:12.0pt;font-family:Arial;color:black"> </span> </b> </p> 
    <h1> <a name="_WARFARIN"> </a> <span __num="333" __label="true"> WARFARIN </span> </h1> 
    <p class="MsoBodyText"> <span style="font-size:11.0pt"> </span> </p> 
    <p class="MsoBodyText" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt"> <span __num="334"> 1. </span> </span> <span style="font-size:7.0pt"> </span> <span style="font-size:11.0pt"> <span __num="335" __label="true"> Give the warfarin on day one of heparinor enoxaparin if long-term anticoagulation is desired.&nbsp; Usually 5.0-7.5 mgPO at night (to ensure absorption on an empty stomach) on Day 1, then 2.5-7.5mg PO QHS (most often 5 mg). Increase in the INR of &gt; 0.3-0.4 units per dayshould result in a dose reduction (otherwise an INR overshoot is likely). </span> </span> </p> 
    <p class="MsoBodyText"> <span style="font-size:11.0pt"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="336"> 2. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="337" __label="true"> Goal for INR: </span> </span> </b> </p> 
    <ul style="margin-top:0in" type="disc"> 
     <li class="MsoNormal" style="color:black;"> <span style="font-size:11.0pt"> <span __num="338" __label="true"> An INR of 2.5-3.5 for mechanical prosthetic valves or recurrent systemic thromboembolism </span> </span> </li> 
     <li class="MsoNormal" style="color:black;"> <span style="font-size:11.0pt"> <span __num="339" __label="true"> INR of 2.0-3.0 for most others (uncomplicated DVT/PE). </span> </span> </li> 
    </ul> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="340"> 3. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="341" __label="true"> Information about the patient's past warfarin dosing history willhelp you titrate appropriately. Congestive heart failure, liver disease,vitamin K deficiency and certain medications influence warfarin response.Tailor the duration of warfarin therapy to the individual and the indication –usually three months to life. </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal"> <i> <span style="font-size:9.0pt;font-family:Arial;color:black"> <span __num="342" __label="true"> Hirsh J, Dalen J, et al.&nbsp; Oral anticoagulants: mechanism ofaction, clinical effectiveness, and optimal therapeutic range.&nbsp; Chest.2001 Jan;119(1 Suppl):8S-21S. </span> </span> </i> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <span style="font-size:14.0pt;font-family:&quot;Times New Roman&quot;;color:blue;"> <br clear="all" style="page-break-before:always"> </span> 
    <h1> <a name="_OUTPATIENT_THERAPY_FOR_1"> </a> <a name="_OUTPATIENT_THERAPY_FOR"> </a> <span __num="343" __label="true"> OUTPATIENTTHERAPY FOR VENOUS THROMBOEMBOLISM </span> </h1> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="344"> 1. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="345" __label="true"> Indications: </span> </span> </b> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="346"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="347" __label="true"> Clinically stable patients with DVT or PEdocumented with imaging study. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="348"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="349" __label="true"> Patients must be motivated and interestedin home self-injection and frequent follow-up. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="350"> 2. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="351" __label="true"> Contraindications: </span> </span> </b> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="352"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="353" __label="true"> Co-morbid conditions: Active peptic ulcerdisease, bleeding in last 14 days, brain metastases, CVA in last 10 days,blindness, CNS or cord injury/surgery in last 10 days, family bleeding diathesis,patient weight &lt;35 kg, platelets &lt; 80K or fall of &gt; 40%. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="354"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="355" __label="true"> Anesthesia: Spinal or epidural anesthesiain past 3 days. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="356"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="357" __label="true"> Medication conflicts: prior sensitivity toheparin, concomitant thrombolytic therapy, need for high-dose NSAIDs other thanibuprofen, naproxen, or Celebrex®.&nbsp; Vioxx® may result in warfarinsensitivity. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="358"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="359" __label="true"> Cognition problems: inability to maintaindiary, inject medications, reliably follow medication schedules, recognize changein health status, or understand directions from home health team. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="360"> 3. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="361" __label="true"> Initial therapy: </span> </span> </b> <span style="font-size:11.0pt;color:black"> <span __num="362" __label="true"> enoxaparin (1 mg/kg SQ q12h) plus warfarin (5 mg PO qhs; 7.5 mg POqhs if &gt; 85 kg). </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="363"> 4. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="364" __label="true"> Maintenance algorithm: </span> </span> </b> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.25in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="365"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="366" __label="true"> Continue enoxaparin until patient hasreceived five days of enoxaparin and has two consecutive INR &gt; 2.0. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="367"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="368" __label="true"> Adjust warfarin to keep INR in desiredrange. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="369"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="370" __label="true"> Check PT/INR frequently after day 2 untilpatient is on stable dose of warfarin. </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <span style="font-size:14.0pt;font-family:&quot;Times New Roman&quot;;color:blue;"> <br clear="all" style="page-break-before:always"> </span> 
    <h1> <a name="_SUPRATHERAPEUTIC_PT/PTT"> </a> <span __num="371" __label="true"> SUPRATHERAPEUTIC PT/PTT </span> </h1> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="372"> 1. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="373" __label="true"> Differential diagnosis </span> </span> </b> <span style="font-size:11.0pt;color:black"> <b> <span __num="374" __label="true"> for prolonged PT: </span> </b> <span __num="375" __label="true"> warfarin, liver disease, poor nutrition,vitamin K deficiency (antibiotics, nutritional, fat malabsorption), deficiencyor inhibitor for factors II, V, VII, or X, DIC, heparin bolus. </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="376"> 2. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="377" __label="true"> Differential diagnosis </span> </span> </b> <span style="font-size:11.0pt;color:black"> <b> <span __num="378" __label="true"> for prolonged PTT: </span> </b> <span __num="379" __label="true"> heparin, congenital deficiency of VIII,IX, XI, von Willebrand’s disease, anti-phospholipid antibody, inhibitor to anyfactor except VII, liver disease, DIC. </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="380"> 3. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="381" __label="true"> Use oral vitamin K to correct mild to moderate PT prolongation.Correction occurs within 10-12 hours. Subcutaneous vitamin K is as good as IVvitamin K, minus the risk of anaphylaxis. </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="382"> 4. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="383" __label="true"> FFP lasts 4-6 hours (need to give concomitant vitamin K). </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="384"> 5. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="385" __label="true"> Bebulin is a plasma-derived concentrate of factors II, VII, IX,and X.&nbsp; It should be used in life threatening bleeds associated withwarfarin.&nbsp; Dose Bebulin ~50 U/kg IV push (need to give concomitant vitaminK). </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="386"> 6. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="387" __label="true"> For heparin associated bleeding: </span> </span> </b> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="388"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="389" __label="true"> Unfractionated heparin: Protamine 1 mg forevery 100 units heparin given. Dose by adding the amount given during eachprior hour divided by 2 </span> <sup> <span __num="390" __label="true"> number of hours back </span> </sup> <span __num="391" __label="true"> .&nbsp; For example, apatient on a heparin drip at 500 units/hour for 3 hours (without a bolus) wouldhave approximately (500/2 </span> <sup> <span __num="392" __label="true"> 0 </span> </sup> <span __num="393" __label="true"> )+(500/2 </span> <sup> <span __num="394" __label="true"> 1 </span> </sup> <span __num="395" __label="true"> )+(500/2 </span> <sup> <span __num="396" __label="true"> 2 </span> </sup> <span __num="397" __label="true"> )=&nbsp; 500 + (500/2) + (500/4) = 875 units of circulating heparin.&nbsp;Therfore, the patient should be given 8-9 mg of protamine. </span> </span> </p> 
    <p class="MsoBodyText2" style="margin-left:.5in;text-indent:-.5in"> <span style="font-family:Symbol"> <span __num="398"> · </span> </span> <span style="font-size:7.0pt"> </span> <span __num="399" __label="true"> Enoxaparin: 1mg:1mg. Protamine may reverse 40-50% of the drug effect. </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <table border="0" cellpadding="0" cellspacing="0" style="margin-left:41.4pt; border-collapse:collapse;"> 
     <tbody> 
      <tr> 
       <td style="width:74.7pt;border-top:black 1.5pt;  border-left:black 1.5pt;border-bottom:windowtext .5pt;border-right:windowtext .5pt;  border-style:solid;padding:0in 5.4pt 0in 5.4pt" valign="top" width="125"> <p align="center" class="MsoNormal" style="text-align:center"> <b> <span style="font-size:11.0pt;color:#3366FF"> <span __num="400"> INR </span> </span> </b> </p> </td> 
       <td style="width:57.25pt;border-top:solid black 1.5pt;  border-left:none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="95"> <p align="center" class="MsoNormal" style="text-align:center"> <b> <span style="font-size:11.0pt;color:#3366FF"> <span __num="401"> Bleeding </span> </span> </b> </p> </td> 
       <td style="width:194.15pt;border-top:solid black 1.5pt;  border-left:none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="324"> <p align="center" class="MsoNormal" style="text-align:center"> <b> <span style="font-size:11.0pt;color:#3366FF"> <span __num="402"> Vitamin K </span> </span> </b> </p> </td> 
       <td style="width:75.9pt;border-top:solid black 1.5pt;  border-left:none;border-bottom:solid windowtext .5pt;border-right:solid black 1.5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="127"> <p align="center" class="MsoNormal" style="text-align:center"> <b> <span style="font-size:11.0pt;color:#3366FF"> <span __num="403"> FFP </span> </span> </b> </p> </td> 
      </tr> 
      <tr> 
       <td style="width:74.7pt;border-top:none;border-left:  solid black 1.5pt;border-bottom:solid black .25pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="125"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="404"> Normal – 5.9 </span> </span> </p> </td> 
       <td style="width:57.25pt;border-top:none;border-left:  none;border-bottom:solid black .25pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="95"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="405"> None </span> </span> </p> </td> 
       <td style="width:194.15pt;border-top:none;border-left:  none;border-bottom:solid black .25pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="324"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="406"> Not indicated </span> </span> </p> </td> 
       <td style="width:75.9pt;border-top:none;border-left:  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="127"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="407"> Not indicated </span> </span> </p> </td> 
      </tr> 
      <tr> 
       <td style="width:74.7pt;border-top:none;border-left:  solid black 1.5pt;border-bottom:solid black .25pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="125"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="408"> 6.0 – 9.9 </span> </span> </p> </td> 
       <td style="width:57.25pt;border-top:none;border-left:  none;border-bottom:solid black .25pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="95"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="409"> None </span> </span> </p> </td> 
       <td style="width:194.15pt;border-top:none;border-left:  none;border-bottom:solid black .25pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="324"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="410"> Oral: 0.5 – 2.5 mg </span> </span> </p> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="411"> SC: 0.5 – 1.0 mg </span> </span> </p> </td> 
       <td style="width:75.9pt;border-top:none;border-left:  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="127"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="412"> Not indicated </span> </span> </p> </td> 
      </tr> 
      <tr> 
       <td style="width:74.7pt;border-top:none;border-left:  solid black 1.5pt;border-bottom:solid black .25pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="125"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="413"> &gt; 10 </span> </span> </p> </td> 
       <td style="width:57.25pt;border-top:none;border-left:  none;border-bottom:solid black .25pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="95"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="414"> None </span> </span> </p> </td> 
       <td style="width:194.15pt;border-top:none;border-left:  none;border-bottom:solid black .25pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="324"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="415"> SC: 3 mg total, in divided doses of 1 mg </span> </span> </p> </td> 
       <td style="width:75.9pt;border-top:none;border-left:  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="127"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="416"> Not indicated </span> </span> </p> </td> 
      </tr> 
      <tr> 
       <td style="width:74.7pt;border-top:none;border-left:  solid black 1.5pt;border-bottom:solid black 1.5pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="125"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="417"> &gt; 20 </span> </span> </p> </td> 
       <td style="width:57.25pt;border-top:none;border-left:  none;border-bottom:solid black 1.5pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="95"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="418"> Yes </span> </span> </p> </td> 
       <td style="width:194.15pt;border-top:none;border-left:  none;border-bottom:solid black 1.5pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="324"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="419"> SC: 10 mg </span> </span> </p> </td> 
       <td style="width:75.9pt;border-top:none;border-left:  none;border-bottom:solid black 1.5pt;border-right:solid black 1.5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="127"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="420"> 10 – 20 cc/kg </span> </span> </p> </td> 
      </tr> 
     </tbody> 
    </table> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <h1> <a name="_UREMIC_BLEEDING"> </a> <span __num="421" __label="true"> UREMIC BLEEDING </span> </h1> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="422"> 1. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="423" __label="true"> Tips: </span> </span> </b> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="424"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="425" __label="true"> Keep hematocrit &gt; 24% </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="426"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="427" __label="true"> Keep platelets &gt; 75K </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="428"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="429" __label="true"> FFP may be helpful if bleeding occurs inthe setting of an elevated INR </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="430"> 2. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="431" __label="true"> Therapies: </span> </span> </b> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="432"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="433" __label="true"> Dialysis </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="434"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="435" __label="true"> Conjugated estrogen 0.6 mg/kg IV QD x 5days </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="436"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="437" __label="true"> DDAVP 0.3 mcg/kg IV q12 hours x 2 </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <h1> <a name="_BLOOD_PRODUCTS_–"> </a> <span style="font-size:11.0pt;color:black"> </span> <br clear="all" style="page-break-before:always"> <span __num="438" __label="true"> BLOOD PRODUCTS – COMPONENTS </span> </h1> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="439"> 1. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="440" __label="true"> Premeds: </span> </span> </b> <span style="font-size:11.0pt;color:black"> <span __num="441" __label="true"> consider pre-medicating with Benadryl 25 mg PO/IV and Tylenol 650 mg PO/PRbefore each unit. </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="442"> 2. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="443" __label="true"> Packed red blood cells (PRBC): </span> </span> </b> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="444"> · </span> </span> <span style="font-size:7.0pt"> </span> <span style="font-size:11.0pt;color:black"> <span __num="445" __label="true"> Most plasma removed. One unit should raise the hematocrit by 3points or hemoglobin by 1 g/dL. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="446"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt"> <span __num="447" __label="true"> Leuko-poor/leuko-filtered red blood cells have mostWBCs removed to make it less antigenic. Use in patients prone to transfusionreactions and in patients requiring multiple transfusions (bone marrowtransplant, leukemia, chemotherapy). </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="448"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="449" __label="true"> Washed red blood cells have WBC almost allremoved. Use as for leuko-poor RBC; note that they are more expensive.&nbsp;Used for patients with allergic reaction to transfusions. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="450"> · </span> </span> <span style="font-size:7.0pt"> </span> <span style="font-size:11.0pt;color:black"> <span __num="451" __label="true"> Irradiated blood cells have lymphocytes killed, decreasinglikelihood of graft-versus host disease (GVHD) in bone marrow transplantpatients. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="452"> · </span> </span> <span style="font-size:7.0pt"> </span> <span style="font-size:11.0pt"> <span __num="453" __label="true"> CMVnegative blood used for patients who are CMV negative and are pre-transplant orpost-transplant. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="454"> 3. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="455" __label="true"> Platelets: </span> </span> </b> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="456"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="457" __label="true"> A 6-pack should&nbsp; ideally raiseplatelet count by 50-60K; For dysfunctional platelets (e.g. in uremia), DDAVPis usually given at 0.3 mcg/kg IV q12-24 hours x 2. Do not correct plateletsfor paracentesis. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="458"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="459" __label="true"> Indications: </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="460"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="461" __label="true"> Platelets &lt; 10-20K for non-bleedingpatient. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="462"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="463" __label="true"> Platelets &lt; 50K for bleeding, pre-op,or pre-procedure. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="464"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="465" __label="true"> Platelets &lt; 75K for uremic bleedingpatients. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="466"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="467" __label="true"> Platelets &lt; 100K for CNS or intraocularbleed. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="468"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="469" __label="true"> Cross-matched platelets may be used whenpatient has been sensitized to random-donor platelets and no longer bumps theirplatelet counts after transfusion; cross-matching typically takes at least 1-2days as well as lab medicine approval at most institutions. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="470"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="471" __label="true"> Always check a 1 hour post-transfusionplatelet count to ensure a response and to monitor for alloimmunization. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoBodyText2" style="margin-left:.25in;text-indent:-.25in"> <span __num="472"> 4. </span> <span style="font-size:7.0pt"> </span> <b> <span __num="473" __label="true"> Fresh frozen plasma(FFP): </span> </b> </p> 
    <p class="MsoBodyText" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="474"> · </span> </span> <span style="font-size:7.0pt"> </span> <span style="font-size:11.0pt"> <span __num="475" __label="true"> Ahigh PT is frequently encountered in end-stage liver disease. It is generallyokay to leave a high PT alone when a patient is not bleeding. For those withrefractory bleeding, use an FFP drip—the half-life of FFP is about 4-6 hours. </span> </span> </p> 
    <p class="MsoBodyText" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="476"> · </span> </span> <span style="font-size:7.0pt"> </span> <span style="font-size:11.0pt"> <span __num="477" __label="true"> FFPis indicated if the PT &gt; 18 seconds and is associated with bleeding orplanned procedures. </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <h2 style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;font-style:normal"> <span __num="478"> 5. </span> </span> <span style="font-size:7.0pt;font-style:normal"> </span> <b> <span style="font-size:11.0pt;font-style:normal"> <span __num="479" __label="true"> Cryoprecipitate: </span> </span> </b> </h2> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="480"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="481" __label="true"> Contains factor VIII, von Willebrandfactor, and fibrinogen. </span> </span> </p> 
    <p class="MsoBodyTextIndent" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="482"> · </span> </span> <span style="font-size:7.0pt"> </span> <span style="font-size:11.0pt"> <span __num="483" __label="true"> Useis generally reserved for patients with quantitative fibrinogen deficiency ( </span> <i> <span __num="484" __label="true"> e.g. </span> </i> <span __num="485" __label="true"> DIC) and qualitative fibrinogen deficits ( </span> <i> <span __num="486" __label="true"> e.g. </span> </i> <span __num="487" __label="true"> acquired dysfibrinogenemiaassociated with liver disease). Its use in patients with hemophilia A (factorVIII deficiency) and von Willebrand disease has been supplanted by the use ofspecific factor products that are safer and more efficacious. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="488"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="489" __label="true"> Advantage: you can replete with lessvolume than FFP. </span> </span> </p> 
    <p class="MsoNormal"> <b> <span style="font-size:11.0pt;color:black"> </span> </b> </p> 
    <h6> <i> <span style="font-size:9.0pt;font-family:Arial;font-weight:normal;text-decoration:none;"> <span __num="490" __label="true"> Churchill WH.&nbsp; Transfusiontherapy. In: Scientific American Medicine.&nbsp; Edited by Federman D.&nbsp;New York: Scientific American, 1999. </span> </span> </i> <span style="font-size:11.0pt;font-weight:normal"> <br clear="all" style="page-break-before:always"> </span> </h6> 
    <h6> <span style="font-size:11.0pt;font-weight:normal"> </span> </h6> 
    <h1> <a name="_BLOOD_PRODUCTS_–_1"> </a> <span __num="491" __label="true"> BLOOD PRODUCTS – COMPLICATIONS </span> </h1> 
    <h6> </h6> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="492"> 1. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="493" __label="true"> Work-up: </span> </span> </b> <span style="font-size:11.0pt;color:black"> <span __num="494" __label="true"> forall transfusion reactions consider a workup for a hemolytic reaction: bloodcultures and hemolysis labs, including purple top for Coombs and red top forrepeat type and cross.&nbsp; The blood bank is required to investigate and willhelp. The different types of reactions are listed below. </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="495"> 2. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="496" __label="true"> Acute hemolytic transfusion reaction: </span> </span> </b> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="497"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="498" __label="true"> Preexisting anti-RBC antibodies in therecipient hemolyze donated blood. Usually caused by ABO incompatibility due toa clerical error. Fever and hypotension occur early in the transfusion; chills,flank pain, and dyspnea may occur. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="499"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="500" __label="true"> Stop blood product immediately, as littleas 30 cc can be fatal. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="501"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="502" __label="true"> Provide hemodynamic and renal support. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="503"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="504" __label="true"> Maintain diuresis with IV fluids andfurosemide; consider alkalinization of urine with bicarbonate to prevent renalfailure. Watch K </span> <sup> <span __num="505" __label="true"> + </span> </sup> <span __num="506" __label="true"> , CK. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="507"> 3. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="508" __label="true"> Delayed hemolytic transfusion reaction: </span> </span> </b> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="509"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="510" __label="true"> An extravascular immune-mediated processmediated by noncomplement-binding IgG. Ideally, the “screen” portion of thetype and screen will identified patients susceptible to thiscomplication.&nbsp; Fever, jaundice, and anemia occur 2 days to 2 weeks aftertransfusion. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="511"> 4. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="512" __label="true"> Anaphylaxis: </span> </span> </b> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="513"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="514" __label="true"> This is different from an acute hemolyticreaction.&nbsp; Interestingly, the reaction is not IgE mediated, but caused byimmune-complex activation of complement – by “anaphylatoxins.”&nbsp; Symptomsare anaphylactoid, occur early in transfusion, and include laryngeal edema. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="515"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="516" __label="true"> Stop the transfusion </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="517"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="518" __label="true"> Give epinephrine and steroids </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="519"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="520" __label="true"> Wash subsequent blood products, and avoidFFP </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="521"> 5. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="522" __label="true"> Bacterial contamination: </span> </span> </b> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.25in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="523"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="524" __label="true"> Look for endotoxemia—the onset of highfever/shock within 4 hours of transfusion. Platelets are far more likely to becontaminated with bacteria than blood, because they are stored are roomtemperature. </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="525"> 6. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="526" __label="true"> Acute lung injury: </span> </span> </b> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="527"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <i> <span style="font-size:11.0pt;color:black"> <span __num="528" __label="true"> i.e. </span> </span> </i> <span style="font-size:11.0pt;color:black"> <span __num="529" __label="true"> “noncardiogenic pulmonary edema”. Also termed“TRALI”—transfusion-related acute lung injury.&nbsp; This is caused by donorantibodies against recipient WBCs. Respiratory failure occurs within 6 hours oftransfusion and treatment is supportive. </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="530"> 7. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="531" __label="true"> Febrile nonhemolytic transfusion reaction: </span> </span> </b> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="532"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="533" __label="true"> This is characterized by fever &gt; 1 </span> </span> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="534" __label="true"> ° </span> </span> <span style="font-size:11.0pt;color:black"> <span __num="535" __label="true"> C during or within 2 hours of completingtransfusion. It occurs with 1 in 5 platelet transfusion reactions and is oflimited clinical significance. It is questionable whether it is necessary todiscontinue the transfusion. Caused by antibodies against foreign donorleukocyte antigens. </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="536"> 8. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="537" __label="true"> Urticarial reaction: </span> </span> </b> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="538"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="539" __label="true"> Some say it is okay to continuetransfusion if the patient responds to antihistamines. Again, this is differentfrom—and does not progress to—an anaphylactiod reaction. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="540"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="541" __label="true"> For nonhemolytic reactions: </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="542"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="543" __label="true"> Benadryl 25-50 mg and Tylenol 650 mg formild transfusion reactions. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="544"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="545" __label="true"> Hydrocortisone 50-100 mg IV for moderateand severe reactions. </span> </span> </p> 
    <h5 align="left" style="text-align:left"> <span style="font-weight:normal"> </span> </h5> 
    <h5 align="left" style="text-align:left"> <span style="font-weight:normal"> </span> </h5> 
    <span style="font-size:14.0pt;font-family:&quot;Times New Roman&quot;;color:blue;"> <br clear="all" style="page-break-before:always"> </span> 
    <h1> <a name="_NEUTROPENIC_FEVER:_ABSOLUTE_1"> </a> <a name="_NEUTROPENIC_FEVER:_ABSOLUTE"> </a> <span __num="546" __label="true"> NEUTROPENIC FEVER: ABSOLUTE NEUTROPHILCOUNT &lt; 500 </span> </h1> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="547"> 1. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="548" __label="true"> If patient has HIV, see </span> <i> <a href="HospH2002_C10.htm#HIV_Fever"> <span __num="549" __label="true"> InfectiousDiseases: HIV and fever </span> </a> </i> <span __num="550" __label="true"> . </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoHeading7" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;font-weight:normal;text-decoration:none;"> <span __num="551"> 2. </span> </span> <span style="font-size:7.0pt;font-weight:normal;text-decoration:none;"> </span> <span style="font-size:11.0pt;text-decoration:none;"> <span __num="552" __label="true"> Non-bone marrowtransplant patients: </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="553"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="554" __label="true"> Obtain blood culture x 2, urine culture,sputum Gram stain and culture, </span> <i> <span __num="555" __label="true"> C. difficile </span> </i> <span __num="556" __label="true"> toxin if patient has been onantibiotics, and CXR. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="557"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="558" __label="true"> Order neutropenic precautions (no rectals,no flowers, no fruit), neutropenic diet, mouth care with Peridex 10 cc sw/spbid, Nystatin 10 cc sw/sw qid or Mycelex troche 1 qid, and Tylenol 650 mg q 4-6hour prn. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="559"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="560" __label="true"> Consider monotherapy with broad-spectrumantibiotics such as ceftazidime, cefipime or anti-pseudomonal beta-lactam.Cover for Gram negative bacteria including Pseudomonas.&nbsp; Also cover Grampositives such as Staph aureus and Strep viridans. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="561"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="562" __label="true"> If prolonged neutropenia, consider fungalinfection and adding amphotericin B (typically 1 mg/kg IV qd). </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="563"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="564" __label="true"> For nosocomial acquisition, suspected IVcatheter infection, known colonization with MRSA/PRSP, (+) blood culture forGram positive cocci, or a hypotensive patient, consider covering MRSA by addingvancomycin. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt"> <span __num="565"> - </span> </span> <span style="font-size:7.0pt"> </span> <span style="font-size:11.0pt"> <span __num="566" __label="true"> Double-cover documented Pseudomonas byadding an aminoglycoside or a fluoroquinolone, such as ciprofloxacin. Thefluoroquinolone is preferable given the renal toxicity of aminoglycosides. </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt"> </span> </p> 
    <h6 style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;font-weight:normal;text-decoration:none;"> <span __num="567"> 3. </span> </span> <span style="font-size:7.0pt;font-weight:normal;text-decoration:none;"> </span> <span style="font-size:11.0pt;text-decoration:none;"> <span __num="568" __label="true"> Bone marrow transplant patients: </span> </span> <span style="font-size:11.0pt;font-weight:normal;text-decoration:none;"> <span __num="569" __label="true"> the guidelines above still apply, except for the following: </span> </span> </h6> 
    <h6 style="margin-left:.5in;text-indent:-.25in"> <span style="font-size:11.0pt;font-family:Symbol;font-weight:normal;text-decoration:none;"> <span __num="570"> · </span> </span> <span style="font-size:7.0pt;font-weight:normal;text-decoration:none;"> </span> <span style="font-size:11.0pt;font-weight:normal;text-decoration:none;"> <span __num="571" __label="true"> Most hospitalsthat have a bone marrow transplant unit have an antibiotic algorithm that youshould follow when treating bone marrow transplant patients with neutropenicfever. </span> </span> </h6> 
    <h6 style="margin-left:.5in;text-indent:-.25in"> <span style="font-size:11.0pt;font-family:Symbol;font-weight:normal;text-decoration:none;"> <span __num="572"> · </span> </span> <span style="font-size:7.0pt;font-weight:normal;text-decoration:none;"> </span> <span style="font-size:11.0pt;font-weight:normal;text-decoration:none;"> <span __num="573" __label="true"> The patients most likelyto suffer from full blown sepsis syndrome are those who arepenicillin-allergic. </span> </span> </h6> 
    <p class="MsoNormal" style="margin-left:.25in"> <span style="font-size:11.0pt"> </span> </p> 
    <p class="MsoNormal"> </p> 
    <span style="font-size:14.0pt;font-family:&quot;Times New Roman&quot;;color:blue;"> <br clear="all" style="page-break-before:always"> </span> 
    <h1> <a name="_SICKLE_CELL_PAIN"> </a> <span __num="574" __label="true"> SICKLE CELL PAIN CRISIS </span> </h1> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> <span __num="575" __label="true"> Your hospitalstaff typically know these patients well.&nbsp; Often, the patient’s primary physicianhas contracted with the patient for an individualized pain protocol.&nbsp;Consider consultation with the hematologist or pain service to get the exactdetails (if they exist).&nbsp; Don’t be surprised by massive opiate toleranceand the need to rapidly escalate the analgesia dose required for relief:remember, physicians typically under-treat pain.&nbsp; Unlike most opioids,such as morphine and oxycodone, codeine and hydrocodone have ceilings beyondwhich increasing doses will not result in increasing analgesia. </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="576"> 1. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="577" __label="true"> Tips: </span> </span> </b> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="578"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="579" __label="true"> Stroke, MI, persistent priapism, orintractable pain characterize acute vaso-occlusive crises. Exchange transfusionis indicated in these cases. Also, multi-organ failure requires urgent exchangetransfusion. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="580"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="581" __label="true"> If patient with frequent episodes of paincrisis, consider hydroxyurea as prophylaxis. </span> </span> </p> 
    <ul style="margin-top:0in" type="disc"> 
     <li class="MsoNormal" style="color:black;"> <span style="font-size:11.0pt"> <span __num="582" __label="true"> In the past, the dogma for treating sickle cell crises called for aggressive fluids, oxygen, and even bicarbonate infusions as methods to reverse the “sickling” process in the red blood cells.&nbsp; However, we have since learned that the event that led to the sickle crisis (and thus the “sickling”) has already occurred by the time the patient comes into the ER.&nbsp; Therefore, these measures are unlikely to be helpful and may be harmful (see below). </span> </span> </li> 
    </ul> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <h4 style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;font-weight:normal"> <span __num="583"> 2. </span> </span> <span style="font-size:7.0pt;font-weight:normal"> </span> <span style="font-size:11.0pt"> <span __num="584" __label="true"> Orders: </span> </span> </h4> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="585"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="586" __label="true"> IV: moderate hypotonic ( </span> <i> <span __num="587" __label="true"> e.g. D </span> <sub> <span __num="588" __label="true"> 5 </span> </sub> <span __num="589" __label="true"> ½NS </span> </i> <span __num="590" __label="true"> )hydration. </span> <i> <span __num="591" __label="true"> Aggressive hydration can lead to or exacerbate acute chestsyndrome </span> </i> <span __num="592" __label="true"> . </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="593"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="594" __label="true"> DIET: NPO; advance diet as tolerated. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="595"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="596" __label="true"> NURSING: O </span> <sub> <span __num="597"> 2 </span> </sub> <span __num="598" __label="true"> 0-4 L/min by NC.(If respiratory status is compromised, remember acute chest syndrome. A newpulmonary infiltrate, fever, chest pain, cough, tachypnea and cough arecharacteristic). </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.25in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="599"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="600" __label="true"> LAB: CBC, reticulocyte count, cultures,electrolytes, BUN, creatinine, bilirubin, U/A, CXR.&nbsp; Draw red-top tube fortype and hold. (If patient is to be transfused, alert the blood bank that thepatient has sickle cell disease; these patients will be screened morethoroughly to avoid alloimmunization associated with frequent transfusions). </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="601"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="602" __label="true"> MEDS:Folic acid 1 mg PO QD and analgesic </span> <i> <span __num="603" __label="true"> dujour. </span> </i> <span __num="604" __label="true"> Avoid Demerol: these patients will inevitably require hugedoses, and are at greatly increased risk of seizures. </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="605"> 3. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="606" __label="true"> Try to determine precipitating factor(s): stress, dehydration,drug use, infection, hypoxia, MI, etc. Although, remember that many of thesepatients come in and out of the hospital for "routine" pain criseswithout specific precipitants. While pain crises often present withnon-specific elevations in WBC and low-grade fevers, there always is thepotential for something bad to be going on. Therefore complete work up ofconcomitant infection is important. </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="607"> 4. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="608" __label="true"> Acute chest syndrome: </span> </span> </b> <span style="font-size:11.0pt;color:black"> <span __num="609" __label="true"> This is one of the dreaded complications of sickle cell diseaseand a leading cause of death in adults with this disease.&nbsp; You shouldthink of this diagnosis in any patient with cough, chest pain, wheezing,shortness of breath, fever, and/or new infiltrate on CXR who has a history ofsickle cell disease.&nbsp; Etiology is not fully known, but thought to involvemicro/macro vascular infarction, pulmonary fat emboli, and concurrentviral/bacterial infection.&nbsp; Management primarily consists of supportivecare, bronchodilators, treatment of coexisting infection, and transfusions ifneeded.&nbsp; In addition, a simple transfusion may be adequate, but if thepatient’s clinical situation worsens an exchange transfusion may be needed. </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal"> <i> <span style="font-size:9.0pt;font-family:Arial;color:black"> <span __num="610" __label="true"> Vichinsky EP, Neumayr LD, et al.&nbsp;&nbsp; Causes and outcomesof the acute chest syndrome in sickle cell disease. National Acute ChestSyndrome Study Group.&nbsp; N Engl J Med. 2000 Jun 22;342(25):1855-65. </span> </span> </i> </p> 
    <h5 align="left" style="text-align:left"> <span style="font-weight:normal"> </span> </h5> 
    <span style="font-size:14.0pt;font-family:&quot;Times New Roman&quot;;color:blue;"> <br clear="all" style="page-break-before:always"> </span> 
    <h1> <a name="_THROMBOCYTOPENIA"> </a> <span __num="611" __label="true"> THROMBOCYTOPENIA </span> </h1> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="612"> 1. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="613" __label="true"> Defined </span> </span> </b> <span style="font-size:11.0pt;color:black"> <span __num="614" __label="true"> asplatelet count &lt; 150K. Generally, platelets &gt; 50K are not associated withsignificant bleeding, and spontaneous bleeding rarely happens with platelets&gt;10-20K in the absence of coagulopathy or qualitative platelet defect. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="615"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="616" __label="true"> Avoid intramuscular injections, rectalexams, suppositories, and enemas. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="617"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="618" __label="true"> Avoid drugs that interfere with plateletfunction (e.g. NSAIDs/ASA, certain beta-lactam antibiotics). </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="619"> 2. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="620" __label="true"> History: </span> </span> </b> <span style="font-size:11.0pt;color:black"> <span __num="621" __label="true"> “B”-symptoms (such as fevers, night sweats, weight loss), GI bleed, epistaxis. </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="622"> 3. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="623" __label="true"> Physical examination: </span> </span> </b> <span style="font-size:11.0pt;color:black"> <span __num="624" __label="true"> look for lymphadenopathy, splenomegaly, ecchymoses, petechiae,purpura. Petechiae indicate a significant risk for intracerebral hemorrhage. </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="625"> 4. </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="626" __label="true"> Labs: </span> </span> </b> <span style="font-size:11.0pt;color:black"> <span __num="627" __label="true"> peripheral smear, PT/PTT, LDH (MAHA), BUN/Cr (HUS/TTP). Get HIV, ANA whenindicated, and consider toxoplasmosis, EBV, and CMV serology iflymphadenopathy, splenomegaly, or “B”-symptoms are detected. </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <h6 style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;font-weight:normal;text-decoration:none;"> <span __num="628"> 5. </span> </span> <span style="font-size:7.0pt;font-weight:normal;text-decoration:none;"> </span> <span style="font-size:11.0pt;text-decoration:none;"> <span __num="629" __label="true"> Etiologies: </span> </span> </h6> 
    <h4 style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;font-weight:normal"> <span __num="630"> · </span> </span> <span style="font-size:7.0pt;font-weight:normal"> </span> <span style="font-size:11.0pt"> <span __num="631" __label="true"> Decreased Production </span> </span> </h4> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="632"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="633" __label="true"> Aplastic anemia </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="634"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="635" __label="true"> Megaloblastic anemia: B12 or folatedeficiency </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="636"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="637" __label="true"> Hematologic malignancies: myelodysplasia,leukemia, myeloma </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="638"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="639" __label="true"> Marrow infiltration: lymphoma,myelofibrosis, metastatic tumor, TB, Gaucher's disease </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="640"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="641" __label="true"> Drug-induced: EtOH, thiazides, estrogens,Septra, chemotherapy, cimetidine, famotidine </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="642"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="643" __label="true"> Paroxysmal nocturnal hemoglobinuria (PNH):rare and associated with pancytopenia. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="644"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="645" __label="true"> Infections: mono, influenza, rubella, hemorrhagicfever, sepsis. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;color:black"> <span __num="646"> · </span> </span> <span style="font-size:7.0pt;color:black"> </span> <b> <span style="font-size:11.0pt;color:black"> <span __num="647" __label="true"> Increased Destruction </span> </span> </b> <span style="font-size:11.0pt;color:black"> <span __num="648" __label="true"> : classically associated with largeplatelets on the smear. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.75in"> <span style="font-size:11.0pt;color:black"> <span __num="649"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="650" __label="true"> Immune mediated: </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:1.0in;text-indent:-1.0in"> <span style="font-size:11.0pt;font-family:&quot;Courier New&quot;;color:black"> <span __num="651"> o </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="652" __label="true"> ITP: sending platelet associated antibodyhas low sens/spec, treat with steroids, IVIG, splenectomy </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:1.0in;text-indent:-1.0in"> <span style="font-size:11.0pt;font-family:&quot;Courier New&quot;;color:black"> <span __num="653"> o </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="654" __label="true"> Neoplasia-associated: CLL </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:1.0in;text-indent:-1.0in"> <span style="font-size:11.0pt;font-family:&quot;Courier New&quot;;color:black"> <span __num="655"> o </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="656" __label="true"> Drug-induced: quinidine, heparin (HIT),rifampin, sulfa, indomethacin, gold </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:1.0in;text-indent:-1.0in"> <span style="font-size:11.0pt;font-family:&quot;Courier New&quot;;color:black"> <span __num="657"> o </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="658" __label="true"> SLE, RA </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:1.0in;text-indent:-1.0in"> <span style="font-size:11.0pt;font-family:&quot;Courier New&quot;;color:black"> <span __num="659"> o </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="660" __label="true"> HIV-associated thrombocytopenia </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:1.0in;text-indent:-1.0in"> <span style="font-size:11.0pt;font-family:&quot;Courier New&quot;;color:black"> <span __num="661"> o </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="662" __label="true"> Post-transfusion purpura </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:.75in;text-indent:-.25in"> <span style="font-size:11.0pt;color:black"> <span __num="663"> - </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="664" __label="true"> Non-immune mediated: </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:1.0in;text-indent:-1.0in"> <span style="font-size:11.0pt;font-family:&quot;Courier New&quot;;color:black"> <span __num="665"> o </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="666" __label="true"> DIC: increased PT/PTT and D-dimers,decreased platelet/fibrinogen, hemolytic anemia, prosthetic valves. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:1.0in;text-indent:-1.0in"> <span style="font-size:11.0pt;font-family:&quot;Courier New&quot;;color:black"> <span __num="667"> o </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="668" __label="true"> HUS </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:1.0in;text-indent:-1.0in"> <span style="font-size:11.0pt;font-family:&quot;Courier New&quot;;color:black"> <span __num="669"> o </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="670" __label="true"> TTP: always increased LDH. Decreasedplatelet, and normal PT/PTT. </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:1.0in;text-indent:-1.0in"> <span style="font-size:11.0pt;font-family:&quot;Courier New&quot;;color:black"> <span __num="671"> o </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="672" __label="true"> Pre-ecclampsia/ecclampsia </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:1.0in;text-indent:-.25in"> <span style="font-size:11.0pt;font-family:&quot;Courier New&quot;;color:black"> <span __num="673"> o </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="674" __label="true"> Toxic shock syndrome </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:1.0in;text-indent:-1.0in"> <span style="font-size:11.0pt;font-family:&quot;Courier New&quot;;color:black"> <span __num="675"> o </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="676" __label="true"> Vasculitis </span> </span> </p> 
    <p class="MsoNormal" style="margin-left:1.0in;text-indent:-1.0in"> <span style="font-size:11.0pt;font-family:&quot;Courier New&quot;;color:black"> <span __num="677"> o </span> </span> <span style="font-size:7.0pt;color:black"> </span> <span style="font-size:11.0pt;color:black"> <span __num="678" __label="true"> Infections: rickettsia, CMV, EBV, malaria,sepsis, etc. </span> </span> </p> 
    <h4 style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol;font-weight:normal"> <span __num="679"> · </span> </span> <span style="font-size:7.0pt;font-weight:normal"> </span> <span style="font-size:11.0pt"> <span __num="680" __label="true"> Sequestration </span> </span> <span style="font-size:11.0pt;font-weight:normal"> <span __num="681" __label="true"> : Hypersplenism </span> </span> </h4> 
    <p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="682"> · </span> </span> <span style="font-size:7.0pt"> </span> <b> <span style="font-size:11.0pt"> <span __num="683" __label="true"> Pseudo-thrombocytopenia </span> </span> </b> <span style="font-size:11.0pt"> <span __num="684" __label="true"> :Blood clumping on CBC, need to check smear to rule out </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal"> <i> <span style="font-size:9.0pt;font-family:Arial;color:black"> <span __num="685" __label="true"> George JN, Raskob GE, et al.&nbsp; Drug-induced thrombocytopenia:a systematic review of published case reports. </span> </span> </i> </p> 
    <p class="MsoNormal"> <i> <span style="font-size:9.0pt;font-family:Arial;color:black"> <span __num="686" __label="true"> Ann Intern Med. 1998 Dec 1;129(11):886-90. </span> </span> </i> </p> 
    <p class="MsoNormal"> <b> <span style="font-size:12.0pt;font-family:Arial;color:black"> </span> </b> </p> 
    <b> <span style="font-size:14.0pt;font-family:&quot;Times New Roman&quot;;color:blue;"> <br clear="all" style="page-break-before:always"> </span> </b> 
    <h1> <a name="_HEPARIN-INDUCED_THROMBOCYTOPENIA_(HIT)"> </a> <span __num="687" __label="true"> HEPARIN-INDUCEDTHROMBOCYTOPENIA (HIT) </span> </h1> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <h5 align="left" style="margin-left:.25in;text-align:left;text-indent:-.25in"> <span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;;font-weight:normal;text-decoration:none;"> <span __num="688"> 1. </span> </span> <span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;;font-weight:normal;text-decoration:none;"> </span> <span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;;font-weight:normal;text-decoration:none;"> <span __num="689" __label="true"> There are primarily two types of HIT: </span> </span> </h5> 
    <p class="MsoNormal"> </p> 
    <table border="0" cellpadding="0" cellspacing="0" style="width:382.5pt; margin-left:23.4pt;border-collapse:collapse;" width="638"> 
     <tbody> 
      <tr> 
       <td style="width:148.5pt;border-top:black 1.5pt;  border-left:black 1.5pt;border-bottom:windowtext .5pt;border-right:windowtext .5pt;  border-style:solid;padding:0in 5.4pt 0in 5.4pt" valign="top" width="248"> <p class="MsoNormal"> <span style="color:#3366FF"> </span> </p> </td> 
       <td style="width:81.0pt;border-top:solid black 1.5pt;  border-left:none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="135"> <p class="MsoNormal"> <b> <span style="font-size:11.0pt;color:#3366FF"> <span __num="690"> Type 1 </span> </span> </b> </p> </td> 
       <td style="width:153.0pt;border-top:solid black 1.5pt;  border-left:none;border-bottom:solid windowtext .5pt;border-right:solid black 1.5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="255"> <p class="MsoNormal"> <b> <span style="font-size:11.0pt;color:#3366FF"> <span __num="691"> Type 2 </span> </span> </b> </p> </td> 
      </tr> 
      <tr> 
       <td style="width:148.5pt;border-top:none;border-left:  solid windowtext 1.5pt;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="248"> <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> <span __num="692"> Frequency </span> </span> </p> </td> 
       <td style="width:81.0pt;border-top:none;border-left:  none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="135"> <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> <span __num="693"> 10-20% </span> </span> </p> </td> 
       <td style="width:153.0pt;border-top:none;border-left:  none;border-bottom:solid windowtext .5pt;border-right:solid windowtext 1.5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="255"> <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> <span __num="694"> 1-3% </span> </span> </p> </td> 
      </tr> 
      <tr> 
       <td style="width:148.5pt;border-top:none;border-left:  solid windowtext 1.5pt;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="248"> <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> <span __num="695"> Timing </span> </span> </p> </td> 
       <td style="width:81.0pt;border-top:none;border-left:  none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="135"> <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> <span __num="696"> 1-4 days </span> </span> </p> </td> 
       <td style="width:153.0pt;border-top:none;border-left:  none;border-bottom:solid windowtext .5pt;border-right:solid windowtext 1.5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="255"> <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> <span __num="697"> 5-10 days </span> </span> </p> </td> 
      </tr> 
      <tr> 
       <td style="width:148.5pt;border-top:none;border-left:  solid windowtext 1.5pt;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="248"> <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> <span __num="698"> Nadir of platelet count </span> </span> </p> </td> 
       <td style="width:81.0pt;border-top:none;border-left:  none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="135"> <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> <span __num="699"> 100,000 </span> </span> </p> </td> 
       <td style="width:153.0pt;border-top:none;border-left:  none;border-bottom:solid windowtext .5pt;border-right:solid windowtext 1.5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="255"> <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> <span __num="700"> 30-55,000 </span> </span> </p> </td> 
      </tr> 
      <tr> 
       <td style="width:148.5pt;border-top:none;border-left:  solid windowtext 1.5pt;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="248"> <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> <span __num="701"> Antibody mediated </span> </span> </p> </td> 
       <td style="width:81.0pt;border-top:none;border-left:  none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="135"> <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> <span __num="702"> No </span> </span> </p> </td> 
       <td style="width:153.0pt;border-top:none;border-left:  none;border-bottom:solid windowtext .5pt;border-right:solid windowtext 1.5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="255"> <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> <span __num="703"> Yes </span> </span> </p> </td> 
      </tr> 
      <tr> 
       <td style="width:148.5pt;border-top:none;border-left:  solid windowtext 1.5pt;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="248"> <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> <span __num="704"> Thromboembolic sequelae </span> </span> </p> </td> 
       <td style="width:81.0pt;border-top:none;border-left:  none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="135"> <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> <span __num="705"> None </span> </span> </p> </td> 
       <td style="width:153.0pt;border-top:none;border-left:  none;border-bottom:solid windowtext .5pt;border-right:solid windowtext 1.5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="255"> <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> <span __num="706"> 30-80% </span> </span> </p> </td> 
      </tr> 
      <tr> 
       <td style="width:148.5pt;border-top:none;border-left:  solid windowtext 1.5pt;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="248"> <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> <span __num="707"> Hemorrhagic sequelae </span> </span> </p> </td> 
       <td style="width:81.0pt;border-top:none;border-left:  none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="135"> <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> <span __num="708"> None </span> </span> </p> </td> 
       <td style="width:153.0pt;border-top:none;border-left:  none;border-bottom:solid windowtext .5pt;border-right:solid windowtext 1.5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="255"> <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> <span __num="709"> Rarely </span> </span> </p> </td> 
      </tr> 
      <tr> 
       <td style="width:148.5pt;border-top:none;border-left:  solid windowtext 1.5pt;border-bottom:solid windowtext 1.5pt;border-right:  solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="248"> <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> <span __num="710"> Management </span> </span> </p> </td> 
       <td style="width:81.0pt;border-top:none;border-left:  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext .5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="135"> <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> <span __num="711"> Observe </span> </span> </p> </td> 
       <td style="width:153.0pt;border-top:none;border-left:  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="255"> <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> <span __num="712"> Discontinue heparin and start alternate anticoagulant. </span> </span> </p> </td> 
      </tr> 
     </tbody> 
    </table> 
    <h5 align="left" style="text-align:left"> </h5> 
    <h5 align="left" style="margin-left:.25in;text-align:left;text-indent:-.25in"> <span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;;font-weight:normal;text-decoration:none;"> <span __num="713"> 2. </span> </span> <span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;;font-weight:normal;text-decoration:none;"> </span> <span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;;text-decoration:none;"> <span __num="714" __label="true"> Diagnosis: </span> </span> <span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;;font-weight:normal;text-decoration:none;"> <span __num="715" __label="true"> think of this diagnosis inyour hospitalized patients whose platelet count starts dropping. </span> </span> </h5> 
    <h5 align="left" style="margin-left:.5in;text-align:left;text-indent:-.25in"> <span style="font-size:11.0pt;font-family:Symbol;color:windowtext;font-weight:normal;text-decoration:none;"> <span __num="716"> · </span> </span> <span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;;color:windowtext;font-weight:normal;text-decoration:none;"> </span> <span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;;font-weight:normal;text-decoration:none;"> <span __num="717" __label="true"> You can diagnose HIT type 2 bysending platelet factor 4 antibody, although this syndrome is primarily aclinical diagnosis. </span> </span> </h5> 
    <h5 align="left" style="text-align:left"> <span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;;font-weight:normal;text-decoration:none;"> </span> </h5> 
    <h5 align="left" style="margin-left:.25in;text-align:left;text-indent:-.25in"> <span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;;font-weight:normal;text-decoration:none;"> <span __num="718"> 3. </span> </span> <span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;;font-weight:normal;text-decoration:none;"> </span> <span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;;text-decoration:none;"> <span __num="719" __label="true"> Incidence: </span> </span> <span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;;font-weight:normal;text-decoration:none;"> <span __num="720" __label="true"> HIT occurs less frequently nowwith the increased use of low molecular weight heparin. </span> </span> </h5> 
    <h5 align="left" style="text-align:left"> <span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;;font-weight:normal;text-decoration:none;"> </span> </h5> 
    <h5 align="left" style="margin-left:.25in;text-align:left;text-indent:-.25in"> <span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;;font-weight:normal;text-decoration:none;"> <span __num="721"> 4. </span> </span> <span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;;font-weight:normal;text-decoration:none;"> </span> <span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;;text-decoration:none;"> <span __num="722" __label="true"> Complications: </span> </span> <span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;;font-weight:normal;text-decoration:none;"> <span __num="723" __label="true"> the thrombotic complicationscan be arterial or venous and often occur at sites of preexisting pathology. </span> </span> </h5> 
    <p class="MsoNormal"> </p> 
    <h5 align="left" style="margin-left:.25in;text-align:left;text-indent:-.25in"> <span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;;font-weight:normal;text-decoration:none;"> <span __num="724"> 5. </span> </span> <span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;;font-weight:normal;text-decoration:none;"> </span> <span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;;text-decoration:none;"> <span __num="725" __label="true"> Treatment: </span> </span> <span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;;font-weight:normal;text-decoration:none;"> <span __num="726" __label="true"> includes stopping all heparinproducts (including heparin flushes and coated catheters), and institutingalternate anticoagulation, as these patients are at increased risk ofthrombosis.&nbsp; Choices include danaparoid (a heparinoid) or lepirudin andargatroban (direct thrombin inhibitors). </span> </span> </h5> 
    <h5 align="left" style="text-align:left"> <span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;;font-weight:normal;text-decoration:none;"> </span> </h5> 
    <p class="MsoNormal"> <i> <span style="font-size:9.0pt;font-family:Arial"> <span __num="727" __label="true"> BriegerDB, Mak KH, Kottke-Marchant K, Topol EJ.&nbsp;&nbsp; Heparin-inducedthrombocytopenia.&nbsp; J Am Coll Cardiol. 1998 Jun;31(7):1449-59. </span> </span> </i> </p> 
    <h5 align="left" style="text-align:left"> <span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;;font-weight:normal;text-decoration:none;"> </span> </h5> 
    <h5 align="left" style="text-align:left"> <span style="font-weight:normal"> </span> </h5> 
    <span style="font-size:14.0pt;font-family:&quot;Times New Roman&quot;;color:blue;"> <br clear="all" style="page-break-before:always"> </span> 
    <h1> <a name="_BONE_MARROW_TRANSPLANT"> </a> <span __num="728" __label="true"> BONE MARROW TRANSPLANT (BMT) –POTENTIAL COMPLICATIONS </span> </h1> 
    <p class="MsoNormal"> <span style="font-size:11.0pt"> </span> </p> 
    <table border="0" cellpadding="0" cellspacing="0" style="margin-left:9.9pt; border-collapse:collapse;"> 
     <tbody> 
      <tr style="height:15.3pt"> 
       <td style="width:90.6pt;border-top:black 1.5pt;  border-left:black 1.5pt;border-bottom:windowtext .5pt;border-right:windowtext .5pt;  border-style:solid;padding:0in 5.4pt 0in 5.4pt;height:15.3pt" valign="top" width="151"> <p class="MsoNormal"> <b> <span style="font-size:11.0pt;color:#3366FF"> <span __num="729"> Days post-BMT </span> </span> </b> </p> </td> 
       <td style="width:378.3pt;border-top:solid black 1.5pt;  border-left:none;border-bottom:solid windowtext .5pt;border-right:solid black 1.5pt;  padding:0in 5.4pt 0in 5.4pt;height:15.3pt" valign="top" width="631"> <p class="MsoNormal"> <b> <span style="font-size:11.0pt;color:#3366FF"> <span __num="730"> Complication </span> </span> </b> </p> </td> 
      </tr> 
      <tr style="height:15.3pt"> 
       <td style="width:90.6pt;border-top:none;border-left:  solid black 1.5pt;border-bottom:solid black .25pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt;height:15.3pt" valign="top" width="151"> <p class="MsoNormal"> <span style="font-size:11.0pt"> <span __num="731"> -7 to 21 </span> </span> </p> </td> 
       <td style="width:378.3pt;border-top:none;border-left:  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;  padding:0in 5.4pt 0in 5.4pt;height:15.3pt" valign="top" width="631"> <p class="MsoNormal"> <span style="font-size:11.0pt"> <span __num="732"> Toxicology of preparative regimens (nausea, vomiting, diarrhea, alopecia, mucositis, renal failure, skin breakdown, ARDS, cardiomyopathy) </span> </span> </p> </td> 
      </tr> 
      <tr style="height:15.3pt"> 
       <td style="width:90.6pt;border-top:none;border-left:  solid black 1.5pt;border-bottom:solid black .25pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt;height:15.3pt" valign="top" width="151"> <p class="MsoNormal"> <span style="font-size:11.0pt"> <span __num="733"> 0 to 21 </span> </span> </p> </td> 
       <td style="width:378.3pt;border-top:none;border-left:  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;  padding:0in 5.4pt 0in 5.4pt;height:15.3pt" valign="top" width="631"> <p class="MsoNormal"> <span style="font-size:11.0pt"> <span __num="734"> HSV reactivation, hepatic veno-occlusive disease </span> </span> </p> </td> 
      </tr> 
      <tr style="height:15.3pt"> 
       <td style="width:90.6pt;border-top:none;border-left:  solid black 1.5pt;border-bottom:solid black .25pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt;height:15.3pt" valign="top" width="151"> <p class="MsoNormal"> <span style="font-size:11.0pt"> <span __num="735"> 0 to 28 </span> </span> </p> </td> 
       <td style="width:378.3pt;border-top:none;border-left:  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;  padding:0in 5.4pt 0in 5.4pt;height:15.3pt" valign="top" width="631"> <p class="MsoNormal"> <span style="font-size:11.0pt"> <span __num="736"> Diffuse alveolar hemorrhage, particularly at engraftment </span> </span> </p> </td> 
      </tr> 
      <tr style="height:15.3pt"> 
       <td style="width:90.6pt;border-top:none;border-left:  solid black 1.5pt;border-bottom:solid black .25pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt;height:15.3pt" valign="top" width="151"> <p class="MsoNormal"> <span style="font-size:11.0pt"> <span __num="737"> 0 to 49 </span> </span> </p> </td> 
       <td style="width:378.3pt;border-top:none;border-left:  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;  padding:0in 5.4pt 0in 5.4pt;height:15.3pt" valign="top" width="631"> <p class="MsoNormal"> <span style="font-size:11.0pt"> <span __num="738"> Bacterial and fungal infections </span> </span> </p> </td> 
      </tr> 
      <tr style="height:15.3pt"> 
       <td style="width:90.6pt;border-top:none;border-left:  solid black 1.5pt;border-bottom:solid black .25pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt;height:15.3pt" valign="top" width="151"> <p class="MsoNormal"> <span style="font-size:11.0pt"> <span __num="739"> 28 to 70 </span> </span> </p> </td> 
       <td style="width:378.3pt;border-top:none;border-left:  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;  padding:0in 5.4pt 0in 5.4pt;height:15.3pt" valign="top" width="631"> <p class="MsoNormal"> <span style="font-size:11.0pt"> <span __num="740"> CMV infection </span> </span> </p> </td> 
      </tr> 
      <tr style="height:15.3pt"> 
       <td style="width:90.6pt;border-top:none;border-left:  solid black 1.5pt;border-bottom:solid black .25pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt;height:15.3pt" valign="top" width="151"> <p class="MsoNormal"> <span style="font-size:11.0pt"> <span __num="741"> 14 to 100 </span> </span> </p> </td> 
       <td style="width:378.3pt;border-top:none;border-left:  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;  padding:0in 5.4pt 0in 5.4pt;height:15.3pt" valign="top" width="631"> <p class="MsoNormal"> <span style="font-size:11.0pt"> <span __num="742"> Acute GVHD </span> </span> </p> </td> 
      </tr> 
      <tr style="height:15.3pt"> 
       <td style="width:90.6pt;border-top:none;border-left:  solid black 1.5pt;border-bottom:solid black .25pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt;height:15.3pt" valign="top" width="151"> <p class="MsoNormal"> <span style="font-size:11.0pt"> <span __num="743"> 49 to 100 </span> </span> </p> </td> 
       <td style="width:378.3pt;border-top:none;border-left:  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;  padding:0in 5.4pt 0in 5.4pt;height:15.3pt" valign="top" width="631"> <p class="MsoNormal"> <span style="font-size:11.0pt"> <span __num="744"> Interstitial pneumonitis </span> </span> </p> </td> 
      </tr> 
      <tr style="height:15.3pt"> 
       <td style="width:90.6pt;border-top:none;border-left:  solid black 1.5pt;border-bottom:solid black 1.5pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt;height:15.3pt" valign="top" width="151"> <p class="MsoNormal"> <span style="font-size:11.0pt"> <span __num="745"> 100 to 180 </span> </span> </p> </td> 
       <td style="width:378.3pt;border-top:none;border-left:  none;border-bottom:solid black 1.5pt;border-right:solid black 1.5pt;  padding:0in 5.4pt 0in 5.4pt;height:15.3pt" valign="top" width="631"> <p class="MsoNormal"> <span style="font-size:11.0pt"> <span __num="746"> Chronic GVHD, VZV, PCP </span> </span> </p> </td> 
      </tr> 
     </tbody> 
    </table> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <h1> <a name="_BMT_–_ACUTE"> </a> <span __num="747" __label="true"> BMT – ACUTE GRAFT VS. HOST DISEASE STAGING ANDGRADING </span> </h1> 
    <p class="MsoNormal"> </p> 
    <table border="0" cellpadding="0" cellspacing="0" style="width:454.5pt; margin-left:9.9pt;border-collapse:collapse;" width="758"> 
     <tbody> 
      <tr> 
       <td style="width:42.0pt;border-top:black 1.5pt;  border-left:black 1.5pt;border-bottom:windowtext .5pt;border-right:windowtext .5pt;  border-style:solid;padding:0in 5.4pt 0in 5.4pt" valign="top" width="70"> <p align="center" class="MsoNormal" style="text-align:center"> <b> <span style="font-size:11.0pt;color:#3366FF"> <span __num="748"> Stage </span> </span> </b> </p> </td> 
       <td style="width:131.25pt;border-top:solid black 1.5pt;  border-left:none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="219"> <p align="center" class="MsoNormal" style="text-align:center"> <b> <span style="font-size:11.0pt;color:#3366FF"> <span __num="749"> Skin </span> </span> </b> </p> </td> 
       <td style="width:132.75pt;border-top:solid black 1.5pt;  border-left:none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="221"> <p align="center" class="MsoNormal" style="text-align:center"> <b> <span style="font-size:11.0pt;color:#3366FF"> <span __num="750"> Liver (total bilirubin) </span> </span> </b> </p> </td> 
       <td style="width:148.5pt;border-top:solid black 1.5pt;  border-left:none;border-bottom:solid windowtext .5pt;border-right:solid black 1.5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="248"> <p align="center" class="MsoNormal" style="text-align:center"> <b> <span style="font-size:11.0pt;color:#3366FF"> <span __num="751"> GI </span> </span> </b> </p> </td> 
      </tr> 
      <tr> 
       <td style="width:42.0pt;border-top:none;border-left:solid black 1.5pt;  border-bottom:solid black .25pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="70"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="752"> 1+ </span> </span> </p> </td> 
       <td style="width:131.25pt;border-top:none;border-left:  none;border-bottom:solid black .25pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="219"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="753"> maculopapular rash </span> </span> </p> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="754"> on &lt; 25 % of BSA </span> </span> </p> </td> 
       <td style="width:132.75pt;border-top:none;border-left:  none;border-bottom:solid black .25pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="221"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="755"> 2-3 mg/dl </span> </span> </p> </td> 
       <td style="width:148.5pt;border-top:none;border-left:  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="248"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="756"> diarrhea 500 – 1000 cc/day </span> </span> </p> </td> 
      </tr> 
      <tr> 
       <td style="width:42.0pt;border-top:none;border-left:solid black 1.5pt;  border-bottom:solid black .25pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="70"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="757"> 2+ </span> </span> </p> </td> 
       <td style="width:131.25pt;border-top:none;border-left:  none;border-bottom:solid black .25pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="219"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="758"> maculopapular rash </span> </span> </p> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="759"> on 25-50 % of BSA </span> </span> </p> </td> 
       <td style="width:132.75pt;border-top:none;border-left:  none;border-bottom:solid black .25pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="221"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="760"> 3-6 mg/dl </span> </span> </p> </td> 
       <td style="width:148.5pt;border-top:none;border-left:  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="248"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="761"> diarrhea 1000 – 1500 cc/day </span> </span> </p> </td> 
      </tr> 
      <tr> 
       <td style="width:42.0pt;border-top:none;border-left:solid black 1.5pt;  border-bottom:solid black .25pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="70"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="762"> 3+ </span> </span> </p> </td> 
       <td style="width:131.25pt;border-top:none;border-left:  none;border-bottom:solid black .25pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="219"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="763"> generalized erythroderma </span> </span> </p> </td> 
       <td style="width:132.75pt;border-top:none;border-left:  none;border-bottom:solid black .25pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="221"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="764"> 6-15 mg/dl </span> </span> </p> </td> 
       <td style="width:148.5pt;border-top:none;border-left:  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="248"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="765"> diarrhea &gt; 1500 cc/day </span> </span> </p> </td> 
      </tr> 
      <tr> 
       <td style="width:42.0pt;border-top:none;border-left:solid black 1.5pt;  border-bottom:solid black 1.5pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="70"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="766"> 4+ </span> </span> </p> </td> 
       <td style="width:131.25pt;border-top:none;border-left:  none;border-bottom:solid black 1.5pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="219"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="767"> generalized erythroderma </span> </span> </p> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="768"> and desquamation </span> </span> </p> </td> 
       <td style="width:132.75pt;border-top:none;border-left:  none;border-bottom:solid black 1.5pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="221"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="769"> &gt; 15 mg/dl </span> </span> </p> </td> 
       <td style="width:148.5pt;border-top:none;border-left:  none;border-bottom:solid black 1.5pt;border-right:solid black 1.5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="248"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="770"> severe abdominal pain ± ileus </span> </span> </p> </td> 
      </tr> 
     </tbody> 
    </table> 
    <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> <span __num="771" __label="true"> Use staginginformation above to determine clinical grade on chart below: </span> </span> </p> 
    <p class="MsoNormal"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <table border="0" cellpadding="0" cellspacing="0" style="margin-left:9.9pt; border-collapse:collapse;"> 
     <tbody> 
      <tr> 
       <td style="width:82.65pt;border-top:black 1.5pt;  border-left:black 1.5pt;border-bottom:windowtext .5pt;border-right:windowtext .5pt;  border-style:solid;padding:0in 5.4pt 0in 5.4pt" valign="top" width="138"> <p align="center" class="MsoNormal" style="text-align:center"> <b> <span style="font-size:11.0pt;color:#3366FF"> <span __num="772"> Clinical grade </span> </span> </b> </p> </td> 
       <td style="width:53.8pt;border-top:solid black 1.5pt;  border-left:none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center"> <b> <span style="font-size:11.0pt;color:#3366FF"> <span __num="773"> Skin </span> </span> </b> </p> </td> 
       <td style="width:53.8pt;border-top:solid black 1.5pt;  border-left:none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center"> <b> <span style="font-size:11.0pt;color:#3366FF"> <span __num="774"> Liver </span> </span> </b> </p> </td> 
       <td style="width:53.8pt;border-top:solid black 1.5pt;  border-left:none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center"> <b> <span style="font-size:11.0pt;color:#3366FF"> <span __num="775"> GI </span> </span> </b> </p> </td> 
       <td style="width:223.95pt;border-top:solid black 1.5pt;  border-left:none;border-bottom:solid windowtext .5pt;border-right:solid black 1.5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="373"> <p align="center" class="MsoNormal" style="text-align:center"> <b> <span style="font-size:11.0pt;color:#3366FF"> <span __num="776"> Decrease in clinical performance </span> </span> </b> </p> </td> 
      </tr> 
      <tr> 
       <td style="width:82.65pt;border-top:none;border-left:  solid black 1.5pt;border-bottom:solid black .25pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="138"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="777"> I </span> </span> </p> </td> 
       <td style="width:53.8pt;border-top:none;border-left:none;  border-bottom:solid black .25pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="778"> 1+ to 2+ </span> </span> </p> </td> 
       <td style="width:53.8pt;border-top:none;border-left:none;  border-bottom:solid black .25pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="779"> 0 </span> </span> </p> </td> 
       <td style="width:53.8pt;border-top:none;border-left:none;  border-bottom:solid black .25pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="780"> 0 </span> </span> </p> </td> 
       <td style="width:223.95pt;border-top:none;border-left:  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="373"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="781"> None </span> </span> </p> </td> 
      </tr> 
      <tr> 
       <td style="width:82.65pt;border-top:none;border-left:  solid black 1.5pt;border-bottom:solid black .25pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="138"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="782"> II </span> </span> </p> </td> 
       <td style="width:53.8pt;border-top:none;border-left:none;  border-bottom:solid black .25pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="783"> 1+ to 3+ </span> </span> </p> </td> 
       <td style="width:53.8pt;border-top:none;border-left:none;  border-bottom:solid black .25pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="784"> 1+ </span> </span> </p> </td> 
       <td style="width:53.8pt;border-top:none;border-left:none;  border-bottom:solid black .25pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="785"> 1+ </span> </span> </p> </td> 
       <td style="width:223.95pt;border-top:none;border-left:  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="373"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="786"> Mild </span> </span> </p> </td> 
      </tr> 
      <tr> 
       <td style="width:82.65pt;border-top:none;border-left:  solid black 1.5pt;border-bottom:solid black .25pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="138"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="787"> III </span> </span> </p> </td> 
       <td style="width:53.8pt;border-top:none;border-left:none;  border-bottom:solid black .25pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="788"> 1+ to 3+ </span> </span> </p> </td> 
       <td style="width:53.8pt;border-top:none;border-left:none;  border-bottom:solid black .25pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="789"> 2+ to 3+ </span> </span> </p> </td> 
       <td style="width:53.8pt;border-top:none;border-left:none;  border-bottom:solid black .25pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="790"> 2+ to 3+ </span> </span> </p> </td> 
       <td style="width:223.95pt;border-top:none;border-left:  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="373"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="791"> Marked </span> </span> </p> </td> 
      </tr> 
      <tr> 
       <td style="width:82.65pt;border-top:none;border-left:  solid black 1.5pt;border-bottom:solid black 1.5pt;border-right:solid black .25pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="138"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="792"> IV </span> </span> </p> </td> 
       <td style="width:53.8pt;border-top:none;border-left:none;  border-bottom:solid black 1.5pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="793"> 2+ to 4+ </span> </span> </p> </td> 
       <td style="width:53.8pt;border-top:none;border-left:none;  border-bottom:solid black 1.5pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="794"> 2+ to 4+ </span> </span> </p> </td> 
       <td style="width:53.8pt;border-top:none;border-left:none;  border-bottom:solid black 1.5pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="795"> 2+ to 4+ </span> </span> </p> </td> 
       <td style="width:223.95pt;border-top:none;border-left:  none;border-bottom:solid black 1.5pt;border-right:solid black 1.5pt;  padding:0in 5.4pt 0in 5.4pt" valign="top" width="373"> <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt"> <span __num="796"> Extreme </span> </span> </p> </td> 
      </tr> 
     </tbody> 
    </table> 
    <p align="center" class="MsoNormal" style="text-align:center"> <span style="font-size:11.0pt;color:black"> </span> </p> 
    <p class="MsoFootnoteText"> <i> <span style="font-size:9.0pt;font-family:Arial;color:black"> <span __num="797" __label="true"> Armitage JO. Bone marrow transplantation. N Engl J Med. 1994 Mar24;330(12):827-38. </span> </span> </i> </p> 
    <p class="MsoFootnoteText"> <span style="font-size:11.0pt"> </span> </p> 
    <b> <span style="font-size:14.0pt;font-family:&quot;Times New Roman&quot;;color:blue;"> <br clear="all" style="page-break-before:always"> </span> </b> 
    <h1> <a name="_ONCOLOGIC_EMERGENCIES"> </a> <span __num="798" __label="true"> ONCOLOGIC EMERGENCIES </span> </h1> 
    <p class="MsoFootnoteText"> <b> <span style="font-size:12.0pt;font-family:Arial"> </span> </b> </p> 
    <p class="MsoFootnoteText" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt"> <span __num="799"> 1. </span> </span> <span style="font-size:7.0pt"> </span> <b> <span style="font-size:11.0pt"> <span __num="800" __label="true"> Cord compression: </span> </span> </b> <span style="font-size:11.0pt"> <span __num="801" __label="true"> see </span> <i> <a href="HospH2002_C12.htm#_CORD_COMPRESSION"> <span __num="802" __label="true"> Neurology:Cord compression </span> </a> </i> <span __num="803" __label="true"> for more details.&nbsp; Remember early treatment iskey—dexamethasone, radiation, and neurosurgical evaluation. </span> </span> </p> 
    <p class="MsoFootnoteText"> <span style="font-size:11.0pt"> </span> </p> 
    <p class="MsoFootnoteText" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt"> <span __num="804"> 2. </span> </span> <span style="font-size:7.0pt"> </span> <b> <span style="font-size:11.0pt"> <span __num="805" __label="true"> Neutropenic fever: </span> </span> </b> <span style="font-size:11.0pt"> <span __num="806" __label="true"> see </span> <i> <a href="#_NEUTROPENIC_FEVER:_ABSOLUTE_1"> <span __num="807" __label="true"> Hematology/Oncology:Neutropenic fever </span> </a> <span __num="808"> . </span> </i> </span> </p> 
    <p class="MsoFootnoteText"> <span style="font-size:11.0pt"> </span> </p> 
    <p class="MsoFootnoteText" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt"> <span __num="809"> 3. </span> </span> <span style="font-size:7.0pt"> </span> <b> <span style="font-size:11.0pt"> <span __num="810" __label="true"> Cerebral metastases: </span> </span> </b> <span style="font-size:11.0pt"> <span __num="811" __label="true"> can present as headache, seizures, altered mentalstatus, or focal deficit.&nbsp; Common in breast and lung cancer.&nbsp;Diagnose with head CT.&nbsp; Treat with dexamethasone, radiation, and possiblesurgery.&nbsp; With edema, mass effect, and/or midline shift, consider measuresto control the rise in intracranial pressure (ICP) such as mannitol andhyperventilation. </span> </span> </p> 
    <p class="MsoFootnoteText"> <span style="font-size:11.0pt"> </span> </p> 
    <p class="MsoFootnoteText" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt"> <span __num="812"> 4. </span> </span> <span style="font-size:7.0pt"> </span> <b> <span style="font-size:11.0pt"> <span __num="813" __label="true"> Carcinomatous meningitis: </span> </span> </b> <span style="font-size:11.0pt"> <span __num="814" __label="true"> may present as seizures, focal neurologic deficits,peripheral neuropathy, or altered mental status.&nbsp; Occurs most often with breastcancer, lymphoma, and leukemia.&nbsp; Diagnose&nbsp; with spinal fluidcytology.&nbsp;&nbsp; Treat with intrathecal chemotherapy or whole brainradiation. </span> </span> </p> 
    <p class="MsoFootnoteText"> <span style="font-size:11.0pt"> </span> </p> 
    <p class="MsoFootnoteText" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt"> <span __num="815"> 5. </span> </span> <span style="font-size:7.0pt"> </span> <b> <span style="font-size:11.0pt"> <span __num="816" __label="true"> Superior vena cava (SVC) syndrome: </span> </span> </b> <span style="font-size:11.0pt"> <span __num="817" __label="true"> presents with facial and/or upper extremity edema as wellas dyspnea on exertion.&nbsp; Commonly seen with lung cancer andlymphoma.&nbsp; Diagnose with CT scan (gold standard). &nbsp;Treat withradiation and/or chemotherapy based on tumor type.&nbsp; Surgery is often riskyand dangerous. </span> </span> </p> 
    <p class="MsoFootnoteText"> <span style="font-size:11.0pt"> </span> </p> 
    <p class="MsoFootnoteText" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt"> <span __num="818"> 6. </span> </span> <span style="font-size:7.0pt"> </span> <b> <span style="font-size:11.0pt"> <span __num="819" __label="true"> Hypercalcemia </span> </span> </b> <span style="font-size:11.0pt"> <span __num="820" __label="true"> : Presents gradually with fatigue, anorexia,constipation, polyuria, and confusion.&nbsp; Can occur with squamous cellcarcinomas, breast cancer, small cell lung cancer, and myeloma.&nbsp; Treatwith hydration, lasix, calcitonin and pamidronate if needed. See also </span> <i> <a href="HospH2002_C5.htm#Hyperca"> <span __num="821" __label="true"> Acid-base/Electrolytes: Hypercalcemia </span> </a> </i> <span __num="822"> . </span> </span> </p> 
    <p class="MsoFootnoteText"> <span style="font-size:11.0pt"> </span> </p> 
    <p class="MsoFootnoteText" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt"> <span __num="823"> 7. </span> </span> <span style="font-size:7.0pt"> </span> <b> <span style="font-size:11.0pt"> <span __num="824" __label="true"> Tumor lysis syndrome: </span> </span> </b> <span style="font-size:11.0pt"> <span __num="825" __label="true"> findings include </span> </span> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="826"> ­ </span> </span> <span style="font-size:11.0pt"> <span __num="827" __label="true"> potassium, </span> </span> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="828"> ­ </span> </span> <span style="font-size:11.0pt"> <span __num="829" __label="true"> phosphorous, </span> </span> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="830"> ­ </span> </span> <span style="font-size:11.0pt"> <span __num="831" __label="true"> uric acid, </span> </span> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="832"> ­ </span> </span> <span style="font-size:11.0pt"> <span __num="833" __label="true"> creatinine, and </span> </span> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="834" __label="true"> ¯ </span> </span> <span style="font-size:11.0pt"> <span __num="835" __label="true"> calcium.&nbsp; Often occurs with tumors that are bulky and verychemotherapy-sensitive.&nbsp;&nbsp; Seen often in Burkitt’s lymphoma.&nbsp;Prevent with hydration and allopurinol.&nbsp; If patient develops syndrome,treat electrolyte abnormalities and continue hydration and allopurinol. </span> </span> </p> 
    <p class="MsoFootnoteText"> <span style="font-size:11.0pt"> </span> </p> 
    <p class="MsoFootnoteText" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt"> <span __num="836"> 8. </span> </span> <span style="font-size:7.0pt"> </span> <b> <span style="font-size:11.0pt"> <span __num="837" __label="true"> Hyperviscosity: </span> </span> </b> <span style="font-size:11.0pt"> <span __num="838" __label="true"> patients present with nonspecific CNS symptoms suchas headache, dizziness, somnolence, and blurry vision.&nbsp; More often occursin patient with myeloma, Waldenstrom’s macroglobulinemia, and polycythemiavera.&nbsp;&nbsp; Obtain CSF, head CT to rule out other CNS processes. Treatwith hydration, phlebotomy (for polycythemia vera), and chemotherapy. </span> </span> </p> 
    <p class="MsoFootnoteText"> <span style="font-size:11.0pt"> </span> </p> 
    <p class="MsoFootnoteText" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt"> <span __num="839"> 9. </span> </span> <span style="font-size:7.0pt"> </span> <b> <span style="font-size:11.0pt"> <span __num="840" __label="true"> Leukostasis: </span> </span> </b> <span style="font-size:11.0pt"> <span __num="841" __label="true"> occurs with very high white blood cell count in acuteleukemias.&nbsp; Symptoms include hypoxia, renal insufficiency, altered mentalstatus, and somnolence. Can worsen during induction chemotherapy.&nbsp; ObtainCSF and head CT to rule out other diagnoses.&nbsp; Treat with leukopheresis,hydration, induction chemotherapy, and possibly hydroxyurea.&nbsp; Avoid bloodproduct transfusions as this might worsen symptoms.&nbsp; Wait until after youwhite blood cells have been removed by leukopheresis. </span> </span> </p> 
    <p class="MsoFootnoteText"> <span style="font-size:11.0pt"> </span> </p> 
    <p class="MsoFootnoteText" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt"> <span __num="842"> 10. </span> </span> <span style="font-size:7.0pt"> </span> <b> <span style="font-size:11.0pt"> <span __num="843" __label="true"> DIC: </span> </span> </b> <span style="font-size:11.0pt"> <span __num="844" __label="true"> oftenoccurs in patients with AML (especially M </span> <sub> <span __num="845"> 3 </span> </sub> <span __num="846" __label="true"> variant) andadenocarcinoma patients.&nbsp; Diagnose by PT/PTT, fibrinogen, platelet count,and D-dimers.&nbsp; Treat by correcting deficits—platelet transfusions, FFP,vitamin K, cryoprecipitate.&nbsp; Treat the underlying cause.&nbsp; Heparin isoccasionally used to suppress the consumptive process, but the data on this islimited. </span> </span> </p> 
    <p class="MsoFootnoteText"> <span style="font-size:11.0pt"> </span> </p> 
    <p class="MsoFootnoteText"> <i> <span style="font-size:9.0pt;font-family:Arial"> <span __num="847" __label="true"> UCSFDivision of Hematology/Oncology Housestaff Handbook,1998. </span> </span> </i> </p> 
    <p class="MsoFootnoteText"> <i> <span style="font-size:9.0pt;font-family:Arial"> </span> </i> </p> 
    <p class="MsoFootnoteText"> <i> <span style="font-size:9.0pt;font-family:Arial"> <span __num="848" __label="true"> BrigdenML.&nbsp; Hematologic and oncologic emergencies.&nbsp; Postgrad Med. 2001Mar;109(3):143-6, 151-4, 157-8. </span> </span> </i> </p> 
    <span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;;"> <br clear="all" style="page-break-before:always"> </span> 
    <p class="MsoFootnoteText"> </p> 
    <h1> <a name="_PAIN_MANAGEMENT"> </a> <span __num="849" __label="true"> PAIN MANAGEMENT </span> </h1> 
    <p class="MsoFootnoteText"> <span style="font-size:11.0pt"> </span> </p> 
    <p class="MsoFootnoteText"> <span style="font-size:11.0pt"> <span __num="850"> See </span> <i> <a href="HospH2002_C13.htm#_PAIN_MANAGEMENT"> <span __num="851"> Toxicology </span> </a> </i> </span> </p> 
    <p class="MsoFootnoteText"> <span style="font-size:11.0pt"> </span> </p> 
    <p class="MsoFootnoteText"> <b> <span style="font-size:12.0pt;font-family:Arial"> </span> </b> </p> 
    <h1> <a name="_COMMON_CHEMOTHERAPY_SIDE"> </a> <span __num="852" __label="true"> COMMON CHEMOTHERAPY SIDE EFFECTS </span> </h1> 
    <p class="MsoFootnoteText"> <span style="font-size:11.0pt"> </span> </p> 
    <p class="MsoFootnoteText" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="853"> · </span> </span> <span style="font-size:7.0pt"> </span> <span style="font-size:11.0pt"> <span __num="854" __label="true"> Fornausea and vomiting, see </span> <i> <a href="HospH2002_C8.htm#_NAUSEA"> <span __num="855" __label="true"> Gastroenterology:Nausea </span> </a> </i> <span __num="856" __label="true"> . </span> </span> </p> 
    <p class="MsoFootnoteText" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="857"> · </span> </span> <span style="font-size:7.0pt"> </span> <span style="font-size:11.0pt"> <span __num="858" __label="true"> Anthracyclineantibiotics: cardiac toxicity in accumulated dose (consider evaluation with pretreatmentMUGA or echocardiogram). </span> </span> </p> 
    <p class="MsoFootnoteText" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="859"> · </span> </span> <span style="font-size:7.0pt"> </span> <span style="font-size:11.0pt"> <span __num="860" __label="true"> Cyclophosphamide:hemorrhagic cystitis (pre-treat with mesna). </span> </span> </p> 
    <p class="MsoFootnoteText" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="861"> · </span> </span> <span style="font-size:7.0pt"> </span> <span style="font-size:11.0pt"> <span __num="862" __label="true"> Etoposide:fever, hypotension during infusion, metabolic acidosis after infusion. </span> </span> </p> 
    <p class="MsoFootnoteText" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="863"> · </span> </span> <span style="font-size:7.0pt"> </span> <span style="font-size:11.0pt"> <span __num="864" __label="true"> Cytarabine:severe mucositis, pink rash that can desquamate, renal insufficiency. </span> </span> </p> 
    <p class="MsoFootnoteText" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="865"> · </span> </span> <span style="font-size:7.0pt"> </span> <span style="font-size:11.0pt"> <span __num="866" __label="true"> Cisplatin:renal toxicity, potassium and magnesium wasting. </span> </span> </p> 
    <p class="MsoFootnoteText" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="867"> · </span> </span> <span style="font-size:7.0pt"> </span> <span style="font-size:11.0pt"> <span __num="868" __label="true"> Vincristine:peripheral neuropathy. </span> </span> </p> 
    <p class="MsoFootnoteText" style="margin-left:.25in;text-indent:-.25in"> <span style="font-size:11.0pt;font-family:Symbol"> <span __num="869"> · </span> </span> <span style="font-size:7.0pt"> </span> <span style="font-size:11.0pt"> <span __num="870" __label="true"> Bleomycin:pulmonary fibrosis. </span> </span> </p> 
    <p class="MsoFootnoteText"> <span style="font-size:11.0pt"> </span> </p> 
    <p class="MsoFootnoteText"> </p> 
   </div> 
  </text> 
 </body>
</html>